Scolaris Content Display Scolaris Content Display

Flow diagram of the search and study selection.
Figures and Tables -
Figure 1

Flow diagram of the search and study selection.

Risk of bias summary: review authors' judgements about each risk of bias item for each study.
Figures and Tables -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each study.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figures and Tables -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Comparison 1 Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 1.1

Comparison 1 Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 1 Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 1.2

Comparison 1 Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 2 Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 2.1

Comparison 2 Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 3 Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 3.1

Comparison 3 Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 3 Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 3.2

Comparison 3 Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 4 Active NRT vs placebo ‐ rs 588765 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 4.1

Comparison 4 Active NRT vs placebo ‐ rs 588765 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 5 Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 5.1

Comparison 5 Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 5 Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 5.2

Comparison 5 Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 6 Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 6.1

Comparison 6 Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 6 Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 6.2

Comparison 6 Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 7 Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 7.1

Comparison 7 Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white, Outcome 1 Six‐Month Abstinence.

Comparison 7 Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 7.2

Comparison 7 Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white, Outcome 2 End of Treatment.

Comparison 8 Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 8.1

Comparison 8 Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 8 Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 8.2

Comparison 8 Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 9 Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 9.1

Comparison 9 Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 9 Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 9.2

Comparison 9 Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 10 Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 10.1

Comparison 10 Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 11 Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 11.1

Comparison 11 Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 11 Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 11.2

Comparison 11 Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 12 Bupropion vs placebo ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 12.1

Comparison 12 Bupropion vs placebo ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 12 Bupropion vs placebo ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 12.2

Comparison 12 Bupropion vs placebo ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 13 Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 13.1

Comparison 13 Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 13 Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 13.2

Comparison 13 Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 14 Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 14.1

Comparison 14 Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 14 Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 14.2

Comparison 14 Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 15 Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 15.1

Comparison 15 Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 15 Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 15.2

Comparison 15 Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 16 Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 16.1

Comparison 16 Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 17 Bupropion vs placebo ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 17.1

Comparison 17 Bupropion vs placebo ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 18 Bupropion vs placebo ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 18.1

Comparison 18 Bupropion vs placebo ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 19 Bupropion vs placebo ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 19.1

Comparison 19 Bupropion vs placebo ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 20 Bupropion vs placebo ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 20.1

Comparison 20 Bupropion vs placebo ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 21 Bupropion vs placebo ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 21.1

Comparison 21 Bupropion vs placebo ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 22 Bupropion vs placebo ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 22.1

Comparison 22 Bupropion vs placebo ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 23 Bupropion vs placebo ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 23.1

Comparison 23 Bupropion vs placebo ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 24 Bupropion vs placebo ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 24.1

Comparison 24 Bupropion vs placebo ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 25 Bupropion + any NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 25.1

Comparison 25 Bupropion + any NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 26 Bupropion + any NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 26.1

Comparison 26 Bupropion + any NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 27 Bupropion + any NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 27.1

Comparison 27 Bupropion + any NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 28 Bupropion + any NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 28.1

Comparison 28 Bupropion + any NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 29 Bupropion + any NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 29.1

Comparison 29 Bupropion + any NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 30 Bupropion + any NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 30.1

Comparison 30 Bupropion + any NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 31 Bupropion + any NRT vs placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 31.1

Comparison 31 Bupropion + any NRT vs placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 32 Bupropion + any NRT vs placebo ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 32.1

Comparison 32 Bupropion + any NRT vs placebo ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 33 Bupropion + any NRT vs placebo ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 33.1

Comparison 33 Bupropion + any NRT vs placebo ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 34 Bupropion + any NRT vs placebo ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 34.1

Comparison 34 Bupropion + any NRT vs placebo ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 35 Bupropion + any NRT vs placebo ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 35.1

Comparison 35 Bupropion + any NRT vs placebo ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 36 Bupropion + any NRT vs placebo ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 36.1

Comparison 36 Bupropion + any NRT vs placebo ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 37 Bupropion + any NRT vs placebo ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 37.1

Comparison 37 Bupropion + any NRT vs placebo ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 38 Bupropion + any NRT vs placebo ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 38.1

Comparison 38 Bupropion + any NRT vs placebo ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 39 Bupropion + any NRT vs placebo ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 39.1

Comparison 39 Bupropion + any NRT vs placebo ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 40 Bupropion + any NRT vs placebo ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 40.1

Comparison 40 Bupropion + any NRT vs placebo ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 41 Bupropion + any NRT vs bupropion ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 41.1

Comparison 41 Bupropion + any NRT vs bupropion ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 42 Bupropion + any NRT vs bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 42.1

Comparison 42 Bupropion + any NRT vs bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 43 Bupropion + any NRT vs bupropion ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 43.1

Comparison 43 Bupropion + any NRT vs bupropion ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 44 Bupropion + any NRT vs bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 44.1

Comparison 44 Bupropion + any NRT vs bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 45 Bupropion + any NRT vs bupropion ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 45.1

Comparison 45 Bupropion + any NRT vs bupropion ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 46 Bupropion + any NRT vs bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 46.1

Comparison 46 Bupropion + any NRT vs bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 47 Bupropion + any NRT vs bupropion ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 47.1

Comparison 47 Bupropion + any NRT vs bupropion ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 48 Bupropion + any NRT vs bupropion ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 48.1

Comparison 48 Bupropion + any NRT vs bupropion ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 49 Bupropion + any NRT vs bupropion ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 49.1

Comparison 49 Bupropion + any NRT vs bupropion ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 50 Bupropion + any NRT vs bupropion ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 50.1

Comparison 50 Bupropion + any NRT vs bupropion ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 51 Bupropion + any NRT vs bupropion ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 51.1

Comparison 51 Bupropion + any NRT vs bupropion ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 52 Bupropion + any NRT vs bupropion ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 52.1

Comparison 52 Bupropion + any NRT vs bupropion ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 53 Bupropion + any NRT vs bupropion ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 53.1

Comparison 53 Bupropion + any NRT vs bupropion ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 54 Bupropion + any NRT vs bupropion ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 54.1

Comparison 54 Bupropion + any NRT vs bupropion ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 55 Bupropion + any NRT vs bupropion ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 55.1

Comparison 55 Bupropion + any NRT vs bupropion ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 56 Bupropion + any NRT vs bupropion ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 56.1

Comparison 56 Bupropion + any NRT vs bupropion ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 57 Active NRT ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 57.1

Comparison 57 Active NRT ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 57 Active NRT ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 57.2

Comparison 57 Active NRT ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 58 Active NRT ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 58.1

Comparison 58 Active NRT ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 59 Active NRT ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 59.1

Comparison 59 Active NRT ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 59 Active NRT ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 59.2

Comparison 59 Active NRT ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 60 Active NRT ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 60.1

Comparison 60 Active NRT ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 60 Active NRT ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 60.2

Comparison 60 Active NRT ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 61 Active NRT ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 61.1

Comparison 61 Active NRT ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 61 Active NRT ‐ rs2036527 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 61.2

Comparison 61 Active NRT ‐ rs2036527 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 62 Active NRT ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 62.1

Comparison 62 Active NRT ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 62 Active NRT ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 62.2

Comparison 62 Active NRT ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 63 Active NRT ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 63.1

Comparison 63 Active NRT ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 63 Active NRT ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 63.2

Comparison 63 Active NRT ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 64 Active NRT ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 64.1

Comparison 64 Active NRT ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 64 Active NRT ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 64.2

Comparison 64 Active NRT ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 65 Active NRT‐NMR ‐ non‐Hispanic white or black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 65.1

Comparison 65 Active NRT‐NMR ‐ non‐Hispanic white or black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 65 Active NRT‐NMR ‐ non‐Hispanic white or black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 65.2

Comparison 65 Active NRT‐NMR ‐ non‐Hispanic white or black or African American, Outcome 2 End of Treatment.

Comparison 66 Bupropion ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 66.1

Comparison 66 Bupropion ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 66 Bupropion ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 66.2

Comparison 66 Bupropion ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 67 Bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 67.1

Comparison 67 Bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 67 Bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 67.2

Comparison 67 Bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 68 Bupropion ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 68.1

Comparison 68 Bupropion ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 69 Bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 69.1

Comparison 69 Bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 69 Bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 69.2

Comparison 69 Bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 70 Bupropion ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 70.1

Comparison 70 Bupropion ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 70 Bupropion ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 70.2

Comparison 70 Bupropion ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 71 Bupropion ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 71.1

Comparison 71 Bupropion ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 71 Bupropion ‐ rs2036527 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 71.2

Comparison 71 Bupropion ‐ rs2036527 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 72 Bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 72.1

Comparison 72 Bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 72 Bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 72.2

Comparison 72 Bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 73 Bupropion ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 73.1

Comparison 73 Bupropion ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 73 Bupropion ‐ rs3733829 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 73.2

Comparison 73 Bupropion ‐ rs3733829 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 74 Bupropion ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 74.1

Comparison 74 Bupropion ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 75 Bupropion ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 75.1

Comparison 75 Bupropion ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 76 Bupropion ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 76.1

Comparison 76 Bupropion ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 77 Bupropion ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 77.1

Comparison 77 Bupropion ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 78 Bupropion ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 78.1

Comparison 78 Bupropion ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 79 Bupropion ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 79.1

Comparison 79 Bupropion ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 80 Bupropion ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 80.1

Comparison 80 Bupropion ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 81 Bupropion ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 81.1

Comparison 81 Bupropion ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 82 Bupropion ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 82.1

Comparison 82 Bupropion ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 83 Varenicline ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 83.1

Comparison 83 Varenicline ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 83 Varenicline ‐ rs16969968 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 83.2

Comparison 83 Varenicline ‐ rs16969968 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 84 Varenicline ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 84.1

Comparison 84 Varenicline ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 84 Varenicline ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 84.2

Comparison 84 Varenicline ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 85 Bupropion + any NRT ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 85.1

Comparison 85 Bupropion + any NRT ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 86 Bupropion + any NRT ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 86.1

Comparison 86 Bupropion + any NRT ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 87 Bupropion + any NRT ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 87.1

Comparison 87 Bupropion + any NRT ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 88 Bupropion + any NRT ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 88.1

Comparison 88 Bupropion + any NRT ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 89 Bupropion + any NRT ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 89.1

Comparison 89 Bupropion + any NRT ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 90 Bupropion + any NRT ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 90.1

Comparison 90 Bupropion + any NRT ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 91 Bupropion + any NRT ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 91.1

Comparison 91 Bupropion + any NRT ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 92 Bupropion + any NRT ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 92.1

Comparison 92 Bupropion + any NRT ‐ rs3733829 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 93 Bupropion + any NRT ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 93.1

Comparison 93 Bupropion + any NRT ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 94 Bupropion + any NRT ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 94.1

Comparison 94 Bupropion + any NRT ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 95 Bupropion + any NRT ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 95.1

Comparison 95 Bupropion + any NRT ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 96 Bupropion + any NRT ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 96.1

Comparison 96 Bupropion + any NRT ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 97 Bupropion + any NRT ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 97.1

Comparison 97 Bupropion + any NRT ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 98 Bupropion + any NRT ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 98.1

Comparison 98 Bupropion + any NRT ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 99 Bupropion + any NRT ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 99.1

Comparison 99 Bupropion + any NRT ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 100 Bupropion + any NRT ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 100.1

Comparison 100 Bupropion + any NRT ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 101 Placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 101.1

Comparison 101 Placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 101 Placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 101.2

Comparison 101 Placebo ‐ rs1051730 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 102 Placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 102.1

Comparison 102 Placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 102 Placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 102.2

Comparison 102 Placebo ‐ rs1051730 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 103 Placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 103.1

Comparison 103 Placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 103 Placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 103.2

Comparison 103 Placebo ‐ rs16969968 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 104 Placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 104.1

Comparison 104 Placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 104 Placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 104.2

Comparison 104 Placebo ‐ rs16969968 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 105 Placebo ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 105.1

Comparison 105 Placebo ‐ rs588765 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 105 Placebo ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 105.2

Comparison 105 Placebo ‐ rs588765 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 106 Placebo ‐ rs588765 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 106.1

Comparison 106 Placebo ‐ rs588765 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 106 Placebo ‐ rs588765 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 106.2

Comparison 106 Placebo ‐ rs588765 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 107 Placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 107.1

Comparison 107 Placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 107 Placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 107.2

Comparison 107 Placebo ‐ rs2036527 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 108 Placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 108.1

Comparison 108 Placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 108 Placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 108.2

Comparison 108 Placebo ‐ rs2036527 ‐ non‐Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 109 Placebo ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 109.1

Comparison 109 Placebo ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 109 Placebo ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 109.2

Comparison 109 Placebo ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 110 Placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 110.1

Comparison 110 Placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 110 Placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 110.2

Comparison 110 Placebo ‐ rs3733829 ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 111 Placebo ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 111.1

Comparison 111 Placebo ‐ rs7937 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 112 Placebo ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 112.1

Comparison 112 Placebo ‐ rs7937 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 113 Placebo ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 113.1

Comparison 113 Placebo ‐ rs1329650 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 114 Placebo ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 114.1

Comparison 114 Placebo ‐ rs1329650 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 115 Placebo ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 115.1

Comparison 115 Placebo ‐ rs1028936 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 116 Placebo ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 116.1

Comparison 116 Placebo ‐ rs1028936 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 117 Placebo ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 117.1

Comparison 117 Placebo ‐ rs215605 ‐ non‐Hispanic white, Outcome 1 End of Treatment.

Comparison 118 Placebo ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.
Figures and Tables -
Analysis 118.1

Comparison 118 Placebo ‐ rs215605 ‐ non‐Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 119 Placebo ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 119.1

Comparison 119 Placebo ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white, Outcome 1 Six‐Month Abstinence.

Comparison 119 Placebo ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 119.2

Comparison 119 Placebo ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white, Outcome 2 End of Treatment.

Comparison 120 Placebo ‐ NMR ‐ non‐Hispanic white or black or African American, Outcome 1 Six‐Month Abstinence.
Figures and Tables -
Analysis 120.1

Comparison 120 Placebo ‐ NMR ‐ non‐Hispanic white or black or African American, Outcome 1 Six‐Month Abstinence.

Comparison 120 Placebo ‐ NMR ‐ non‐Hispanic white or black or African American, Outcome 2 End of Treatment.
Figures and Tables -
Analysis 120.2

Comparison 120 Placebo ‐ NMR ‐ non‐Hispanic white or black or African American, Outcome 2 End of Treatment.

Summary of findings for the main comparison. Active NRT compared with placebo ‐ rs1051730 ‐ non‐Hispanic white for smoking cessation

Active NRT compared with placebo ‐ rs1051730 ‐ non‐Hispanic white for smoking cessationa

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with active NRT ‐ rs1051730 ‐ non‐Hispanic white

Risk with placebo

Abstinence at end of treatment

Study population

RR 1.63
(1.14 to 2.32)

1391
(2 RCTs)

⊕⊕⊕⊝
MODERATEb,c

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.004 (see results for individual subgroups in below rows)

327 per 1000
(228 to 465)

200 per 1000

Abstinence at end of treatment ‐ homozygous major

Study population

RR 1.09
(0.85 to 1.41)

582
(2 RCTs)

⊕⊕⊝⊝
LOWc,d

For participants with homozygous major genotype, low‐quality evidence suggests no effect.

286 per 1000
(223 to 370)

263 per 1000

Abstinence at end of treatment ‐ heterozygous

Study population

RR 2.13
(1.52 to 2.97)

631
(2 RCTs)

⊕⊕⊕⊝
MODERATEc

For participants with heterozygous genotype, moderate‐quality evidence shows effect in favour intervention.

335 per 1000
(239 to 467)

157 per 1000

Abstinence at end of treatment ‐ homozygous minor

Study population

RR 2.18
(1.04 to 4.58)

178
(2 RCTs)

⊕⊕⊝⊝
LOWc,e

For participants with homozygous minor genotype, low‐quality evidence shows effect in favour intervention.

338 per 1000
(161 to 710)

155 per 1000

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

aThis is the first of seven 'Summary of findings' tables for the main comparison. For a complete list, see the 'Additional summary of findings' section.

bNot downgraded owing to inconsistency, as large statistical heterogeneity can be explained by differences between genotypes.

cDowngraded one level owing to risk of bias: high potential for selection bias in GRPG 1993 due to low fraction of genotyped participants.

dDowngraded one level owing to imprecision: optimal information size criterion is met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

eDowngraded one level owing to imprecision: optimal information size criterion is not met in this stratum. Counts in this stratum are smaller than in a single adequately powered trial.

Figures and Tables -
Summary of findings for the main comparison. Active NRT compared with placebo ‐ rs1051730 ‐ non‐Hispanic white for smoking cessation
Summary of findings 2. Active NRT compared with placebo ‐ rs16969968 ‐ non‐Hispanic white for smoking cessation

Active NRT compared with placebo ‐ rs16969968 ‐ non‐Hispanic white for smoking cessation

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with placebo ‐ rs16969968 ‐ non‐Hispanic white

Risk with active NRT

End of treatment

Study population

RR 1.38
(0.97 to 1.98)

1127
(2 RCTs)

⊕⊕⊕⊝
MODERATEa,b

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.03 (see results for individual subgroups in below rows)

251 per 1000

346 per 1000
(243 to 496)

End of treatment ‐ homozygous major

Study population

RR 1.01
(0.77 to 1.33)

449
(2 RCTs)

⊕⊕⊝⊝
LOWa,c

For participants with homozygous major genotype, low‐quality evidence suggests no effect.

333 per 1000

337 per 1000
(257 to 443)

End of treatment ‐ heterozygous

Study population

RR 1.85
(1.33 to 2.59)

550
(2 RCTs)

⊕⊕⊕⊕
HIGH

For participants with heterozygous genotype, high‐quality evidence shows effect in favour of intervention.

193 per 1000

358 per 1000
(257 to 501)

End of treatment ‐ homozygous minor

Study population

RR 1.80
(0.45 to 7.23)

128
(2 RCTs)

⊕⊕⊝⊝
LOWd

For participants with homozygous minor genotype, low‐quality evidence shows that point estimate favours intervention, but 95% CI crosses null effect.

233 per 1000

420 per 1000
(105 to 1000)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT, randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level owing to imprecision: Optimal information size criterion is met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

bNot downgraded owing to inconsistency, as large statistical heterogeneity can be explained by differences in genotypes.

cDowngraded one level owing to inconsistency: unexplained heterogeneity.

dDowngraded two levels owing to serious imprecision: optimal information size criterion not met, and 95% CIs include the null effect and fail to exclude important benefit or important harm.

Figures and Tables -
Summary of findings 2. Active NRT compared with placebo ‐ rs16969968 ‐ non‐Hispanic white for smoking cessation
Summary of findings 3. Active NRT compared with placebo ‐ rs16969968 ‐ non‐Hispanic black or African American for smoking cessation

Active NRT compared with placebo ‐ rs16969968 ‐ non‐Hispanic black or African American for smoking cessation

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with active NRT ‐ rs16969968 ‐ non‐Hispanic black or African American

Risk with placebo

Abstinence at 6 months

Study population

RR 1.11
(0.55 to 2.26)

709
(2 RCTs)

⊕⊕⊕⊝
MODERATEa,b

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.03 (see results for individual subgroups in below rows)

203 per 1000
(101 to 414)

183 per 1000

Abstinence at 6 months ‐ homozygous major

Study population

RR 1.47
(1.07 to 2.03)

637
(2 RCTs)

⊕⊕⊕⊕
HIGH

For participants with homozygous major genotype, high‐quality evidence shows effect in favour of intervention.

254 per 1000
(185 to 350)

173 per 1000

Abstinence at 6 months ‐ heterozygous or homozygous minor

Study population

RR 0.43
(0.15 to 1.26)

72
(2 RCTs)

⊕⊕⊝⊝
LOWc

For participants with heterozygous or homozygous minor genotype, point estimate favours control, but 95% CI crosses null effect.

117 per 1000
(41 to 344)

273 per 1000

Abstinence at end of treatment

Study population

RR 1.03
(0.36 to 2.94)

709
(2 RCTs)

⊕⊕⊕⊝
MODERATEa,b

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.003 (see results for individual subgroups in below rows)

201 per 1000
(70 to 575)

196 per 1000

Abstinence at end of treatment ‐ homozygous major

Study population

RR 1.57
(1.15 to 2.15)

637
(2 RCTs)

⊕⊕⊕⊕
HIGH

For participants with homozygous major genotype, high‐quality evidence shows effect in favour of intervention.

276 per 1000
(202 to 379)

176 per 1000

Abstinence at end of treatment ‐ heterozygous or homozygous minor

Study population

RR 0.29
(0.10 to 0.86)

72
(2 RCTs)

⊕⊕⊕⊝
MODERATEd

For participants with heterozygous or homozygous minor genotype, moderate‐quality evidence shows effect in favour of control.

105 per 1000
(36 to 313)

364 per 1000

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

aNot downgraded owing to inconsistency, as large statistical heterogeneity can be explained by differences in genotypes.

bDowngraded one level owing to imprecision: Optimal information size criterion is met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

cDowngraded two levels owing to serious imprecision: optimal information size criterion not met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

dDowngraded one level owing to imprecision: low number of events; optimal information size criterion not met.

Figures and Tables -
Summary of findings 3. Active NRT compared with placebo ‐ rs16969968 ‐ non‐Hispanic black or African American for smoking cessation
Summary of findings 4. Active NRT compared with placebo ‐ rs 588765 ‐ non‐Hispanic white for smoking cessation

Active NRT compared with placebo ‐ rs 588765 ‐ non‐Hispanic white for smoking cessation

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with placebo ‐ rs 588765 ‐ non‐Hispanic white

Risk with active NRT

End of treatment

Study population

RR 1.33
(1.04 to 1.71)

923
(2 RCTs)

⊕⊕⊕⊝
MODERATEa

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.92 (see results for individual subgroups in below rows)

211 per 1000

281 per 1000
(220 to 361)

End of treatment ‐ homozygous major

Study population

RR 1.39
(0.89 to 2.16)

296
(2 RCTs)

⊕⊕⊝⊝
LOWb

For participants with homozygous major genotype, low‐quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.

208 per 1000

288 per 1000
(185 to 448)

End of treatment ‐ heterozygous

Study population

RR 1.27
(0.89 to 1.79)

469
(2 RCTs)

⊕⊕⊝⊝
LOWb

For participants with heterozygous genotype, point estimate favours intervention, but 95% CI crosses null effect.

208 per 1000

265 per 1000
(185 to 373)

End of treatment ‐ homozygous minor

Study population

RR 1.50
(0.74 to 3.06)

158
(2 RCTs)

⊕⊕⊝⊝
LOWb

For participants with homozygous minor genotype, low‐quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.

226 per 1000

339 per 1000
(167 to 691)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level owing to imprecision: low number of events; optimal information size criterion not met.

bDowngraded two levels owing to serious imprecision: optimal information size criterion not met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

Figures and Tables -
Summary of findings 4. Active NRT compared with placebo ‐ rs 588765 ‐ non‐Hispanic white for smoking cessation
Summary of findings 5. Active NRT compared with placebo ‐ rs2036527 ‐ non‐Hispanic black or African American for smoking cessation

Active NRT compared with placebo ‐ rs2036527 ‐ non‐Hispanic black or African American for smoking cessation

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with placebo ‐ rs2036527 ‐ non‐Hispanic black or African American

Risk with active NRT

6‐Month abstinence

Study population

RR 1.18
(0.75 to 1.87)

708
(2 RCTs)

⊕⊕⊝⊝
LOWa

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.19 (see results for individual subgroups in below rows)

177 per 1000

208 per 1000
(132 to 330)

6‐Month abstinence ‐ homozygous major

Study population

RR 1.95
(0.46 to 8.26)

425
(2 RCTs)

⊕⊝⊝⊝
VERY LOWa,b

For participants with homozygous major genotype, very low‐quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.

171 per 1000

333 per 1000
(79 to 1000)

6‐Month abstinence ‐ heterozygous or homozygous minor

Study population

RR 0.90
(0.40 to 2.03)

283
(2 RCTs)

⊕⊕⊕⊝
MODERATEc

For participants with heterozygous or homozygous minor genotype, moderate‐quality evidence shows no effect.

185 per 1000

167 per 1000
(74 to 377)

End of treatment

Study population

RR 1.22
(0.77 to 1.93)

708
(2 RCTs)

⊕⊕⊝⊝
LOWa

Pooled results across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.19 (see results for individual subgroups in below rows)

199 per 1000

242 per 1000
(153 to 384)

End of treatment ‐ homozygous major

Study population

RR 2.39
(0.43 to 13.35)

425
(2 RCTs)

⊕⊕⊝⊝
LOWb,c

For participants with homozygous major genotype, low‐quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.

197 per 1000

471 per 1000
(85 to 1000)

End of treatment ‐ heterozygous or homozygous minor

Study population

RR 0.89
(0.55 to 1.46)

283
(2 RCTs)

⊕⊕⊕⊝
MODERATEc

For participants with heterozygous or homozygous minor genotype, moderate‐quality evidence shows no effect.

202 per 1000

179 per 1000
(111 to 294)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

cDowngraded one level owing to imprecision: low number of events; optimal information size criterion not met.

Figures and Tables -
Summary of findings 5. Active NRT compared with placebo ‐ rs2036527 ‐ non‐Hispanic black or African American for smoking cessation
Summary of findings 6. Active NRT compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white for smoking cessation

Active NRT compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white for smoking cessation

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white

Risk with active NRT

6‐Month abstinence

Study population

RR 1.44
(1.08 to 1.92)

900
(2 RCTs)

⊕⊕⊝⊝
LOWa,b

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.85 (see results for individual subgroups in below rows)

141 per 1000

203 per 1000
(152 to 271)

6‐month abstinence ‐ homozygous major

Study population

RR 1.34
(0.93 to 1.93)

566
(2 RCTs)

⊕⊝⊝⊝
VERY LOWa,b,c

For participants with homozygous major genotype, very low‐quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.

155 per 1000

207 per 1000
(144 to 299)

6‐Month abstinence ‐ heterozygous

Study population

RR 1.76
(1.00 to 3.10)

290
(2 RCTs)

⊕⊕⊝⊝
LOWa,b

For participants with heterozygous genotype, low‐quality evidence suggests effect in favour of intervention.

113 per 1000

198 per 1000
(113 to 349)

6‐Month abstinence ‐ homozygous minor

Study population

RR 1.28
(0.40 to 4.11)

44
(2 RCTs)

⊕⊝⊝⊝
VERY LOWa,b,c

For participants with homozygous minor genotype, very low‐quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.

167 per 1000

213 per 1000
(67 to 685)

End of treatment

Study population

RR 1.20
(0.88 to 1.63)

900
(2 RCTs)

⊕⊕⊝⊝
LOWa,b

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity P value = 0.78 (see results for individual subgroups in below rows)

271 per 1000

325 per 1000
(238 to 441)

End of treatment ‐ homozygous major

Study population

RR 1.22
(0.59 to 2.51)

566
(2 RCTs)

⊕⊝⊝⊝
VERY LOWa,b,c

For participants with homozygous major genotype, very low‐quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.

273 per 1000

334 per 1000
(161 to 686)

End of treatment ‐ heterozygous

Study population

RR 1.40
(0.57 to 3.39)

290
(2 RCTs)

⊕⊝⊝⊝
VERY LOWa,b,c

For participants with heterozygous genotype, very low‐quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.

258 per 1000

362 per 1000
(147 to 876)

End of treatment ‐ homozygous minor

Study population

RR 1.02
(0.65 to 1.58)

44
(2 RCTs)

⊕⊕⊝⊝
LOWa,b

For participants with homozygous minor genotype, low‐quality evidence suggests no effect.

333 per 1000

340 per 1000
(217 to 527)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level owing to high risk of bias: high risk of selection bias in GRPG 1993 due to low fraction of genotyped participants.

bDowngraded one level owing to imprecision: low number of events; optimal information size criterion not met.

cDowngraded one level owing to imprecision: 95% CIs include the null effect and fail to exclude important benefit or important harm.

Figures and Tables -
Summary of findings 6. Active NRT compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white for smoking cessation
Summary of findings 7. Active NRT compared with placebo ‐ NMR ‐ non‐Hispanic black and white for smoking cessation

Active NRT compared with placebo ‐ NMR ‐ non‐Hispanic black and white for smoking cessation

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with placebo ‐ NMR ‐ non‐Hispanic black and white

Risk with active NRT

6‐Month abstinence

Study population

RR 1.51
(1.08 to 2.10)

1417
(2 RCTs)

⊕⊕⊕⊝
MODERATEa

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity: P value = 0.29 (see results for individual subgroups in below rows)

99 per 1000

149 per 1000
(107 to 207)

6‐Month abstinence ‐ slow NMR

Study population

RR 1.82
(1.12 to 2.94)

628
(2 RCTs)

⊕⊕⊕⊝
MODERATEa

For participants with slow NMR genotype, moderate‐quality evidence favours intervention.

116 per 1000

211 per 1000
(130 to 341)

6‐Month abstinence ‐ normal NMR

Study population

RR 1.21
(0.78 to 1.87)

789
(2 RCTs)

⊕⊕⊝⊝
LOWb

For participants with normal NMR genotype, point estimate favours intervention, but 95% CI crosses null effect.

85 per 1000

103 per 1000
(66 to 159)

End of treatment

Study population

RR 1.51
(1.19 to 1.90)

1417
(2 RCTs)

⊕⊕⊕⊝
MODERATEa

Pooled result across studies, including all genotypes. Between‐genotype group heterogeneity: P value = 0.52 (see results for individual subgroups in below rows)

136 per 1000

205 per 1000
(162 to 258)

End of treatment ‐ slow NMR

Study population

RR 1.61
(1.18 to 2.20)

847
(2 RCTs)

⊕⊕⊕⊝
MODERATEa

For participants with slow NMR genotype, moderate‐quality evidence favours intervention.

127 per 1000

204 per 1000
(149 to 278)

End of treatment ‐ normal NMR

Study population

RR 1.49
(0.85 to 2.60)

570
(2 RCTs)

⊕⊕⊝⊝
LOWa,b

For participants with normal NMR genotype, point estimate favours intervention, but 95% CI crosses null effect.

149 per 1000

222 per 1000
(127 to 388)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level owing to risk of bias: 755/1532 (49%) participants from Patch Trial (GPRG 1993) were genotyped, which could contribute to selection bias.

bDowngraded one level owing to imprecision: optimal information size criterion is met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

Figures and Tables -
Summary of findings 7. Active NRT compared with placebo ‐ NMR ‐ non‐Hispanic black and white for smoking cessation
Table 1. Glossary of genetic terms

Genetic term

Explanation

Single‐nucleotide polymorphism (SNP)

A single base pair change in the DNA sequence at a particular point compared with the “common” or “wild‐type” sequence (Attia 2009)

Most common form of genetic variation in the genome, in which a single‐base substitution has created 2 forms of a DNA sequence that differ by a single nucleotide (Pearson 2008)

Alleles

Alternate forms of a gene or chromosomal locus that differ in DNA sequence (Pearson 2008)

Genome‐wide association study (GWAS)

Any study of genetic variation across the entire human genome designed to identify genetic association with observable traits or the presence or absence of a disease, usually referring to studies with genetic marker density of 100,000 or more to represent a large proportion of variation in the human genome (Pearson 2008)

Genotype

The genetic constitution of an individual, either overall or at a specific gene (Attia 2009)

Hardy‐Weinberg equilibrium (HWE)

Population distribution of 2 alleles (with frequencies p and q) such that the distribution is stable from generation to generation and genotypes occur at frequencies of p2, 2pq, and q2 for the major allele homozygote, heterozygote, and minor allele homozygote, respectively (Pearson 2008)

Linkage disequilibrium

Measure of association between 2 alleles located near each other on a chromosome, such that they are inherited together more frequently than would be expected by chance (Pearson 2008)

Loci

The site(s) on a chromosome at which the gene for a particular trait is located on a gene at which a particular SNP is located (Attia 2009)

Minor allele

The allele of a biallelic polymorphism that is less frequent in the study population (Pearson 2008)

Major allele

The allele of a biallelic polymorphism that is more frequent in the study population (Pearson 2008)

Pharmacogenetics

The field of studying the genetic basis of drug response and applying this knowledge to clinical practice by guiding drug prescribing

Pharmacogenomics

Similar to pharmacogenetics but uses information across the whole genome

Population stratification

A form of confounding in genetic association studies caused by genetic differences between cases and controls unrelated to disease but due to sampling from populations of different ancestries (Pearson 2008)

Wild‐type allele

The allele at a particular single‐nucleotide polymorphism (SNP) that is most frequent in a population, also called “common” allele (Attia 2009)

DNA = deoxyribonucleic acid; SNP = Single‐nucleotide polymorphism; GWAS = Genome‐wide association study; HWE = Hardy‐Weinberg equilibrium

Figures and Tables -
Table 1. Glossary of genetic terms
Table 2. Polymorphisms of interest, together with their major/minor alleles, stratified by race

Polymorphism

Race group

Gene/Region

SNP or VNTRa

Whiteb

Black or African Americanc

East Asiand

Mexicane

CHRNA3

rs1051730

G/A

G/A

G/A

G/A

CHRNA5

rs16969968

G/A

G/A

G/A

G/A

CHRNA5

rs588765

C/T

C/T

C/T

C/T

CHRNA5

rs2036527

G/A

G/A

G/A

G/A

CHRNB3

rs13280604

A/G

G/A

A/G

A/G

CYP2A6

rs4105144

T/C

T/C

T/C

T/C

CYP2B6

rs6474412

T/C

C/T

T/C

T/C

DBH

rs3025343

G/A

G/A

G/A

G/A

DRD4 (exon 3 48 bp)

SI000224I

4 (0.65), 7 (0.18), 3, 2

4 (0.75), 7 (0.14), 6, 5

4 (0.79), 2 (0.17), 5

7 (0.52), 4 (0.41), 2

EGLN2

rs3733829

A/G

A/G

A/G

G/A

EGLN2

rs7937

T/C

C/T

T/C

T/C

LOC100188947

rs1329650

G/T

G/T

T/G

G/T

LOC100188947

rs1028936

A/C

A/C

C/A

A/C

PDE1C

rs215605

T/G

G/T

G/T

T/G

SLC6A3 (3' 40 bp)

SI000156M

10 (0.69), 9 (0.31)

10 (0.73), 9 (0.21), 3, 8

10 (0.91), 9

10 (0.74), 9 (0.24)

SLC6A4 (Promoter)

SI664268Gf

L (0.62), S (0.38)

L (0.78), S (0.07), 19 (0.15)

L (0.27), S (0.71)

L (0.42), S (0.58)

aSNP rsID and frequencies from the 1000 Genomes Project database (http://analysistools.nci.nih.gov/LDlink/), VNTR UID and frequencies from ALFRED (http://alfred.med.yale.edu/alfred/index.asp).

bGBR or European (PopID = 20, SampID = 20C).

cASW or per VNTR (DRD4, Biaka (PopID = 5, SampID = 5F); SLC6A3, African American (PopID = 98R, SampID = 101C); SLC6A4, Biaka.

dCHB + JPT, or mean of Han and Japanese, for SLC6A3 and SLC6A4, Han (SampID = 9J) and Japanese (SampID = 10B).

eMXL or per VNTR (DRD4, see Table 2, Aguirre‐Samudio 2014; SLC6A3, Hispanic American from ALFRED; SLC6A4, see Table 2, Peralta‐Leal 2012).

fFor Euro, African American and East Asian, extracted from Promoter VNTR + rs25531 Table in ALFRED. L = 16 repeats, S = 14 repeats.

SNP = Single‐nucleotide polymorphism; VNTR = variable number tandem repeat; G = nucleobase guanine; A = nucleobase adenine; C = nucleobase cytosine; T = nucleobase thymine; rsID=reference SNP cluster ID; UID=Unique Identifier, from ALFRED; GBR=British in England and Scotland population description code from 1000 Genomes Project; PopID=Population ID from ALFRED; SampID=Sample ID from ALFRED; ASW=Americans of African Ancestry in SW USA population description code, from 1000 Genomes Project; CHB=Han Chinese in Bejing, China population description code, from 1000 Genomes Project; JPT=Japanese in Tokyo, Japan population description code, from 1000 Genomes Project; Han=Han Chinese living in the San Francisco, California, from ALFRED; MXL=Mexican Ancestry from Los Angeles USA population description code, from 1000 Genomes Project; L=Long (16 repeats); S=Short (14 repeats)

Figures and Tables -
Table 2. Polymorphisms of interest, together with their major/minor alleles, stratified by race
Table 3. Data availability per treatment comparison for the outcome 6‐month abstinence

Treatment comparison

SNP or VNTRa

Ethnicity

Number of studies (individual treatment 1/treatment 2) included

Analysis number

Significant treatment effect

Letter indicates which treatment is favoured:

a = active NRT

b = bupropion

ba = bupropion + active NRT

p = placebo

v = varenicline

P value heterogeneity genotype groups

Active NRT vs placebo

O

HoMa

Het

HoMi

rs1051730

NHW

3 (1023/574)

1.1

a

a

a

0.40

rs16969968

NHB

2 (392/317)

3.1

a

0.03a

rs2036527

NHB

2 (391/317)

5.1

0.36a

DRD4 (exon 3 48 bp)

NHW

2 (453/447)

6.1

a

a

0.72

O

S

N

NMR

NHW or NHB

2 (719/699)

7.1

a

a

0.22

Bupropion vs placebo

O

HoMa

Het

HoMi

rs1051730

NHW

4 (797/532)

8.1

b

b

0.77

NHB

3 (63/63)

9.1

0.80

rs16969968

NHB

2 (294/284)

11.1

0.22a

rs588765

NHW

4 (596/511)

12.1

b

b

0.32

rs2036527

NHW

2 (412/326)

13.1

b

b

0.28

NHB

3 (331/329)

14.1

0.65

rs3733829

NHW

2 (307/264)

15.1

b

b

0.25

Het: heterozygous; HoMa: homozygous major; HoMi: homozygous minor; N: normal NMR; NHB: non‐Hispanic black or African American; NHW: non‐Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; O = overall; SNP: single‐nucleotide polymorphism; VNTR: variable number tandem repeat.

aHomozygous major vs heterozygous + homozygous minor.

Figures and Tables -
Table 3. Data availability per treatment comparison for the outcome 6‐month abstinence
Table 4. Data availability per treatment comparison for the outcome abstinence at end of treatment

Treatment comparison

SNP or VNTRa

Ethnicity

Number of studies (individual treatment 1/treatment 2) included

Analysis number

Significant treatment effect

Letter indicates which treatment is favoured:

a = active NRT

b = bupropion

ba = bupropion + active NRT

p = placebo

v = varenicline

P value heterogeneity genotype groups

Active NRT vs placebo

O

HoMa

Het

HoMi

rs1051730

NHW

2 (912/479)

1.2

a

a

a

0.004

rs16969968

NHW

2 (784/343)

2.1

a

0.02

NHB

2 (392/317)

3.2

a

pb

0.003a

rs588765

NHW

2 (587/336)

4.1

a

0.89

rs2036527

NHB

2 (391/317)

5.2

0.28a

DRD4 (exon 3 48 bp)

NHW

2 (453/447)

6.2

0.79

O

S

N

NMR

NHW or NHB

2 (718/699)

7.2

a

a

0.80

Bupropion vs placebo

O

HoMa

Het

HoMi

rs1051730

NHW

6 (743/636)

8.2

b

b

b

b

0.41

NHB

3 (84/75)

9.2

0.12

rs16969968

NHW

3 (324/233)

10.1

b

b

0.50

NHB

3 (315/296)

11.2

b

bb

0.77a

rs588765

NHW

4 (595/512)

12.2

b

b

0.96

rs2036527

NHW

4 (546/429)

13.2

b

b

b

b

0.20

NHB

4 (352/341)

14.2

b

b

0.38

rs3733829

NHW

4 (440/367)

15.2

b

b

b

0.71

NHB

2 (46/29)

16.1

0.56a

rs7937

NHW

3 (324/233)

17.1

b

b

0.54

NHB

2 (47/29)

18.1

0.92a

rs1329650

NHW

3 (324/235)

19.1

b

b

0.83

NHB

2 (47/29)

20.1

0.59a

rs1028936

NHW

3 (324/235)

21.1

b

b

0.90

NHB

2 (47/29)

22.1

0.37a

rs215605

NHW

3 (324/234)

23.1

b

b

0.43

NHB

2 (47/29)

24.1

0.92a

Bupropion + any NRT vs placebo

O

HoMa

Het

HoMi

rs1051730

NHW

2 (268/176)

25.1

ba

ba

0.77

NHB

2 (40/29)

26.1

0.07a

rs16969968

NHW

2 (266/175)

27.1

ba

ba

0.77

NHB

2 (40/29)

28.1

0.35a

rs2036527

NHW

2 (267/176)

29.1

ba

ba

0.95

NHB

2 (40/29)

30.1

0.59

rs3733829

NHW

2 (266/175)

31.1

ba

ba

0.83

NHB

2 (48/21[ES1] )

32.1

0.45a

rs7937

NHW

2 (268/174)

33.1

ba

0.62

NHB

2 (40/29)

34.1

0.98a

rs1329650

NHW

2 (266/176)

35.1

ba

ba

0.90

NHB

2 (40/29)

36.1

0.78a

rs1028936

NHW

2 (268/176)

37.1

ba

ba

0.88

NHB

2 (40/29)

38.1

0.89a

rs215605

NHW

2 (267/175)

39.1

ba

ba

0.79

NHB

2 (40/28)

40.1

0.52a

Bupropion + any NRT vs bupropion

O

HoMa

Het

HoMi

rs1051730

NHW

2 (268/265)

41.1

0.97

NHB

2 (40/47)

42.1

0.41a

rs16969968

NHW

2 (266/265)

43.1

0.98

NHB

2 (40/47)

44.1

0.57a

rs2036527

NHW

2 (267/265)

45.1

0.99

NHB

2 (40/47)

46.1

0.61a

rs3733829

NHW

2 (267/264)

47.1

0.82

NHB

2 (48/46)

48.1

b

0.58a

rs7937

NHW

2 (268/265)

49.1

0.69

NHB

2 (40/47)

50.1

0.85a

rs1329650

NHW

2 (266/265)

51.1

0.66

NHB

2 (40/47)

52.1

0.49a

rs1028936

NHW

2 (268/265)

53.1

0.60

NHB

2 (40/47)

54.1

0.49a

rs215605

NHW

2 (267/265)

55.1

0.50

NHB

2 (40/47)

56.1

0.75a

Het: heterozygous; HoMa: homozygous major; HoMi: homozygous minor; N: normal NMR; NHB: non‐Hispanic black or African American; NHW: non‐Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; O: overall; SNP: single‐nucleotide polymorphism; VNTR: variable number tandem repeat.

aHomozygous major vs heterozygous + homozygous minor.

bHeterozygous + homozygous minor.

Figures and Tables -
Table 4. Data availability per treatment comparison for the outcome abstinence at end of treatment
Table 5. Data availability per treatment group for the outcome 6‐month abstinence

Treatment group

SNP or VNTRa

Ethnicity

Number of studies (individuals in homozygous major/heterozygous/homozygous minor) included

Analysis number

Significant treatment effect

Letter indicates which genotype is favoured:

ma = genotype group with 1 or more major alleles

mi = homozygous minor

s = slow NMR

n = normal NMR

P value heterogeneity in genotype comparisons

Active NRT

MaMi

HetMi

rs1051730

NHW

7 (1352/1025/310)

57.1

0.93

NHB

2 (181/50/6)

58.1

0.98

rs16969968

NHB

2 (353/39a)

59.1

N/A

rs588765

NHW

3 (286/399/147)

60.1

0.76

rs2036527

NHW

2 (369/447/132)

61.1

0.79

NHB

2 (232/159a)

62.1

N/A

DRD4 (exon 3 48 bp)

NHW

3 (798/253/68)

63.1

0.74

SLC6A4 (Promoter)

NHW

2 (277/465/184)

64.1

0.62

Normal vs slow

NMR

NHW and NHB

2 (400/318)

65.1

s

N/A

Bupropion

rs1051730

NHW

4 (220/294/96)

66.1

0.82

NHB

2 (43/20a)

67.1

N/A

rs16969968

NHB

2 (261/33a)

69.1

N/A

rs588765

NHW

4 (195/292/109)

70.1

0.80

rs2036527

NHW

2 (143/204/65)

71.1

0.87

NHB

3 (187/144a)

72.1

N/A

rs3733829

NHW

2 (146/116/45)

73.1

0.65

Varenicline

rs16969968

NHW

2 (269/349/89)

83.1

0.81

rs588765

NHW

2 (234/345/120)

84.1

0.90

Placebo

rs1051730

NHW

6 (377/441/156)

101.1

0.54

NHB

2 (49/14a)

102.1

N/A

rs16969968

NHW

2 (132/181/30)

103.1

0.63

NHB

3 (519/65a)

104.1

N/A

rs588765

NHW

5 (253/340/130)

105.1

0.92

NHB

2 (275/291a)

106.1

N/A

rs2036527

NHW

2 (117/166/43)

107.1

0.81

NHB

4 (373/256a)

108.1

N/A

DRD4 (exon 3 48 bp)

NHW

3 (361/186/26)

109.1

0.44

rs3733829

NHW

2 (122/102/40)

110.1

0.60

SLC6A4 (Promoter)

NHW

2 (128/23a)

119.1

N/A

Normal vs slow

NMR

NHW and NHB

2 (389/310)

120.1

N/A

HetMi: heterozygous vs homozygous minor; MaMi: homozygous major vs homozygous minor; NHB: non‐Hispanic black or African American; NHW: non‐Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; NS: normal NMR vs slow NMR; SNP: single‐nucleotide polymorphism; VNTR: variable number tandem repeat.

aHeterozygous and homozygous minor combined.

Figures and Tables -
Table 5. Data availability per treatment group for the outcome 6‐month abstinence
Table 6. Data availability per treatment group for the outcome abstinence at end of treatment

Treatment group

SNP or VNTRa

Ethnicity

Number of studies (individuals in homozygous major/heterozygous/homozygous minor) included

Analysis number

Significant treatment effect

Letter indicates which genotype is favored:

ma = genotype group with 1 or more major alleles

mi = homozygous minor

s = slow NMR

n = normal NMR

P value heterogeneity in genotype comparisons

Active NRT

MaMi

HetMi

rs1051730

NHW

5 (917/1008/283)

57.2

0.64

rs16969968

NHB

2 (353/39a)

59.2

mab

N/A

rs588765

NHW

3 (286/399/147)

60.2

0.97

rs2036527

NHW

2 (369/447/132)

61.2

0.74

NHB

2 (232/159a)

62.2

mab

N/A

DRD4 (exon 3 48 bp)

NHW

3 (798/253/68)

63.2

0.72

SLC6A4 (Promoter)

NHW

2 (277/465/184)

64.2

0.83

Normal vs slow

NMR

NHW and NHB

2 (400/318)

65.2

N/A

Bupropion

rs1051730

NHW

6 (263/357/123)

66.2

0.59

NHB

3 (58/26a)

67.2

N/A

rs16969968

NHW

3 (108/164/52)

68.1

0.51

NHB

3 (279/36a)

69.2

N/A

rs588765

NHW

4 (195/292/109)

70.2

0.65

rs2036527

NHW

4 (185/269/92)

71.2

0.53

NHB

4 (200/152a)

72.2

N/A

rs3733829

NHW

4 (203/181/56)

73.2

0.87

NHB

2 (35/11a)

74.1

N/A

rs7937

NHW

3 (86/165/73)

75.1

0.66

NHB

2 (20/24/3)

76.1

0.62

rs1329650

NHW

3 (161/138/25)

77.1

0.90

NHB

2 (42/5a)

78.1

N/A

rs1028936

NHW

3 (212/103/9)

79.1

1.00

NHB

2 (42/5a)

80.1

N/A

rs215605

NHW

3 (125/154/45)

81.1

0.94

NHB

2 (31/16a)

82.1

N/A

Varenicline

rs16969968

NHW

2 (269/349/89)

83.2

0.94

rs588765

NHW

2 (234/345/120)

84.2

0.84

Bupropion + any NRT

rs1051730

NHW

2 (113/130/25)

85.1

0.96

NHB

2 (33/7a)

86.1

N/A

rs16969968

NHW

2 (113/130/23)

87.1

0.98

NHB

2 (36/4a)

88.1

N/A

rs2036527

NHW

2 (111/132/24)

89.1

0.82

NHB

2 (23/12/5)

90.1

0.87

rs3733829

NHW

2 (114/123/30)

91.1

0.52

NHB

2 (30/10a)

92.1

mib

N/A

rs7937

NHW

2 (74/140/54)

93.1

0.95

NHB

2 (13/27a)

94.1

N/A

rs1329650

NHW

2 (149/96/21)

95.1

mi

0.67

NHB

2 (34/6a)

96.1

N/A

rs1028936

NHW

2 (183/75/10)

97.1

0.67

NHB

2 (34/6a)

98.1

N/A

rs215605

NHW

2 (105/119/43)

99.1

0.25

NHB

2 (18/22a)

100.1

Placebo

rs1051730

NHW

7 (378/441/164)

101.2

0.71

NHB

3 (63/20a)

102.2

N/A

rs16969968

NHW

4 (169/227/49)

103.2

0.83

NHB

4 (530/66a)

104.2

mib

N/A

rs588765

NHW

5 (254/296/108)

105.2

0.34

NHB

2 (277/289a)

106.2

N/A

rs2036527

NHW

4 (154/213/62)

107.2

0.90

NHB

5 (378/263a)

108.2

N/A

DRD4 (exon 3 48 bp)

NHW

3 (361/186/26)

109.2

0.65

rs3733829

NHW

4 (164/152/51)

110.2

0.53

rs7937

NHW

3 (73/120/40)

111.1

0.67

NHB

2 (18/11a)

112.1

N/A

rs1329650

NHW

3 (119/106/10)

113.1

0.99

NHB

2 (21/8a)

114.1

N/A

rs1028936

NHW

3 (158/72/5)

115.1

0.79

NHB

2 (23/6a)

116.1

N/A

rs215605

NHW

3 (94/105/35)

117.1

0.70

NHB

2 (18/11a)

118.1

N/A

SLC6A4 (Promoter)

NHW

2 (128/23a)

119.2

N/A

Normal vs slow

NMR

NHW and NHB

2 (400/318)

120.2

N/A

HetMi: heterozygous vs homozygous minor; MaMi: homozygous major vs homozygous minor; NHB: non‐Hispanic black or African American; NHW: non‐Hispanic white; NS: normal NMR vs slow NMR; SNP: single‐nucleotide polymorphism; VNTR: variable number tandem repeat; NMR = nicotine metabolite ratio.

aHeterozygous and homozygous minor combined.

bHomozygous major vs heterozygous and homozygous minor.

Figures and Tables -
Table 6. Data availability per treatment group for the outcome abstinence at end of treatment
Comparison 1. Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

3

1597

Risk Ratio (M‐H, Random, 95% CI)

1.42 [1.16, 1.75]

1.1 Homozygous Major

3

659

Risk Ratio (M‐H, Random, 95% CI)

1.27 [0.93, 1.72]

1.2 Heterozygous

3

731

Risk Ratio (M‐H, Random, 95% CI)

1.48 [1.08, 2.01]

1.3 Homozygous Minor

3

207

Risk Ratio (M‐H, Random, 95% CI)

2.07 [1.06, 4.01]

2 End of Treatment Show forest plot

2

1391

Risk Ratio (M‐H, Random, 95% CI)

1.63 [1.14, 2.32]

2.1 Homozygous Major

2

582

Risk Ratio (M‐H, Random, 95% CI)

1.09 [0.85, 1.41]

2.2 Heterozygous

2

631

Risk Ratio (M‐H, Random, 95% CI)

2.13 [1.52, 2.97]

2.3 Homozygous Minor

2

178

Risk Ratio (M‐H, Random, 95% CI)

2.18 [1.04, 4.58]

Figures and Tables -
Comparison 1. Active NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white
Comparison 2. Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

1127

Risk Ratio (M‐H, Random, 95% CI)

1.38 [0.97, 1.98]

1.1 Homozygous Major

2

449

Risk Ratio (M‐H, Random, 95% CI)

1.01 [0.77, 1.33]

1.2 Heterozygous

2

550

Risk Ratio (M‐H, Random, 95% CI)

1.85 [1.33, 2.59]

1.3 Homozygous Minor

2

128

Risk Ratio (M‐H, Random, 95% CI)

1.80 [0.45, 7.23]

Figures and Tables -
Comparison 2. Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white
Comparison 3. Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

709

Risk Ratio (M‐H, Random, 95% CI)

1.11 [0.55, 2.26]

1.1 Homozygous Major

2

637

Risk Ratio (M‐H, Random, 95% CI)

1.47 [1.07, 2.03]

1.2 Heterozygous or Homozygous Minor

2

72

Risk Ratio (M‐H, Random, 95% CI)

0.43 [0.15, 1.26]

2 End of Treatment Show forest plot

2

709

Risk Ratio (M‐H, Random, 95% CI)

1.03 [0.36, 2.94]

2.1 Homozygous Major

2

637

Risk Ratio (M‐H, Random, 95% CI)

1.57 [1.15, 2.15]

2.2 Heterozygous or Homozygous Minor

2

72

Risk Ratio (M‐H, Random, 95% CI)

0.29 [0.10, 0.86]

Figures and Tables -
Comparison 3. Active NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American
Comparison 4. Active NRT vs placebo ‐ rs 588765 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

923

Risk Ratio (M‐H, Random, 95% CI)

1.33 [1.04, 1.71]

1.1 Homozygous Major

2

296

Risk Ratio (M‐H, Random, 95% CI)

1.39 [0.89, 2.16]

1.2 Heterozygous

2

469

Risk Ratio (M‐H, Random, 95% CI)

1.27 [0.89, 1.79]

1.3 Homozygous Minor

2

158

Risk Ratio (M‐H, Random, 95% CI)

1.50 [0.74, 3.06]

Figures and Tables -
Comparison 4. Active NRT vs placebo ‐ rs 588765 ‐ non‐Hispanic white
Comparison 5. Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

708

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.75, 1.87]

1.1 Homozygous Major

2

425

Risk Ratio (M‐H, Random, 95% CI)

1.95 [0.46, 8.26]

1.2 Heterozygous or Homozygous Minor

2

283

Risk Ratio (M‐H, Random, 95% CI)

0.90 [0.40, 2.03]

2 End of Treatment Show forest plot

2

708

Risk Ratio (M‐H, Random, 95% CI)

1.22 [0.77, 1.93]

2.1 Homozygous Major

2

425

Risk Ratio (M‐H, Random, 95% CI)

2.39 [0.43, 13.35]

2.2 Heterozygous or Homozygous Minor

2

283

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.55, 1.46]

Figures and Tables -
Comparison 5. Active NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American
Comparison 6. Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

900

Risk Ratio (M‐H, Random, 95% CI)

1.44 [1.08, 1.92]

1.1 Homozygous Major

2

566

Risk Ratio (M‐H, Random, 95% CI)

1.34 [0.93, 1.93]

1.2 Heterozygous

2

290

Risk Ratio (M‐H, Random, 95% CI)

1.76 [1.00, 3.10]

1.3 Homozygous Minor

2

44

Risk Ratio (M‐H, Random, 95% CI)

1.28 [0.40, 4.11]

2 End of Treatment Show forest plot

2

900

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.88, 1.63]

2.1 Homozygous Major

2

566

Risk Ratio (M‐H, Random, 95% CI)

1.22 [0.59, 2.51]

2.2 Heterozygous

2

290

Risk Ratio (M‐H, Random, 95% CI)

1.40 [0.57, 3.39]

2.3 Homozygous Minor

2

44

Risk Ratio (M‐H, Random, 95% CI)

1.02 [0.65, 1.58]

Figures and Tables -
Comparison 6. Active NRT vs placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white
Comparison 7. Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

1417

Risk Ratio (M‐H, Random, 95% CI)

1.51 [1.08, 2.10]

1.1 Slow NMR

2

628

Risk Ratio (M‐H, Random, 95% CI)

1.82 [1.12, 2.94]

1.2 Normal NMR

2

789

Risk Ratio (M‐H, Random, 95% CI)

1.21 [0.78, 1.87]

2 End of Treatment Show forest plot

2

1417

Risk Ratio (M‐H, Random, 95% CI)

1.51 [1.19, 1.90]

2.1 Slow NMR

2

847

Risk Ratio (M‐H, Random, 95% CI)

1.61 [1.18, 2.20]

2.2 Normal NMR

2

570

Risk Ratio (M‐H, Random, 95% CI)

1.49 [0.85, 2.60]

Figures and Tables -
Comparison 7. Active NRT vs placebo ‐ NMR ‐ non‐Hispanic black and white
Comparison 8. Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

4

1329

Risk Ratio (M‐H, Random, 95% CI)

1.34 [1.11, 1.61]

1.1 Homozygous Major

4

495

Risk Ratio (M‐H, Random, 95% CI)

1.24 [0.94, 1.65]

1.2 Heterozygous

4

633

Risk Ratio (M‐H, Random, 95% CI)

1.44 [1.09, 1.91]

1.3 Homozygous Minor

4

201

Risk Ratio (M‐H, Random, 95% CI)

1.31 [0.57, 2.99]

2 End of Treatment Show forest plot

6

1379

Risk Ratio (M‐H, Random, 95% CI)

1.40 [1.19, 1.64]

2.1 Homozygous Major

6

496

Risk Ratio (M‐H, Random, 95% CI)

1.32 [1.05, 1.67]

2.2 Heterozygous

6

655

Risk Ratio (M‐H, Random, 95% CI)

1.36 [1.03, 1.79]

2.3 Homozygous Minor

6

228

Risk Ratio (M‐H, Random, 95% CI)

1.83 [1.20, 2.79]

Figures and Tables -
Comparison 8. Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic white
Comparison 9. Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

124

Risk Ratio (M‐H, Random, 95% CI)

1.50 [0.75, 3.00]

1.1 Homozygous Major

2

92

Risk Ratio (M‐H, Random, 95% CI)

1.61 [0.71, 3.64]

1.2 Heterozygous

2

32

Risk Ratio (M‐H, Random, 95% CI)

1.30 [0.32, 5.34]

2 End of Treatment Show forest plot

3

157

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.70, 2.06]

2.1 Homozygous Major

3

117

Risk Ratio (M‐H, Random, 95% CI)

1.76 [0.96, 3.23]

2.2 Heterozygous

3

40

Risk Ratio (M‐H, Random, 95% CI)

0.68 [0.32, 1.44]

Figures and Tables -
Comparison 9. Bupropion vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American
Comparison 10. Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

557

Risk Ratio (M‐H, Random, 95% CI)

1.42 [1.13, 1.77]

1.1 Homozygous Major

3

198

Risk Ratio (M‐H, Random, 95% CI)

1.35 [0.92, 1.99]

1.2 Heterozygous

3

276

Risk Ratio (M‐H, Random, 95% CI)

1.46 [1.04, 2.04]

1.3 Homozygous Minor

3

83

Risk Ratio (M‐H, Random, 95% CI)

2.55 [0.95, 6.85]

Figures and Tables -
Comparison 10. Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic white
Comparison 11. Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

578

Risk Ratio (M‐H, Random, 95% CI)

1.30 [0.84, 2.00]

1.1 Homozygous Major

2

512

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.75, 1.87]

1.2 Heterozygous or Homozygous Minor

2

66

Risk Ratio (M‐H, Random, 95% CI)

2.82 [0.76, 10.45]

2 End of Treatment Show forest plot

3

611

Risk Ratio (M‐H, Random, 95% CI)

1.95 [1.23, 3.08]

2.1 Homozygous Major

3

541

Risk Ratio (M‐H, Random, 95% CI)

2.12 [1.44, 3.10]

2.2 Heterozygous or Homozygous Minor

3

70

Risk Ratio (M‐H, Random, 95% CI)

1.65 [0.33, 8.36]

Figures and Tables -
Comparison 11. Bupropion vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American
Comparison 12. Bupropion vs placebo ‐ rs588765 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

4

1107

Risk Ratio (M‐H, Random, 95% CI)

1.37 [1.12, 1.67]

1.1 Homozygous Major

4

384

Risk Ratio (M‐H, Random, 95% CI)

1.33 [0.85, 2.08]

1.2 Heterozygous

4

526

Risk Ratio (M‐H, Random, 95% CI)

1.25 [0.95, 1.65]

1.3 Homozygous Minor

4

197

Risk Ratio (M‐H, Random, 95% CI)

1.95 [1.18, 3.22]

2 End of Treatment Show forest plot

4

1107

Risk Ratio (M‐H, Random, 95% CI)

1.36 [1.13, 1.65]

2.1 Homozygous Major

4

385

Risk Ratio (M‐H, Random, 95% CI)

1.37 [1.05, 1.79]

2.2 Heterozygous

4

525

Risk Ratio (M‐H, Random, 95% CI)

1.31 [0.86, 2.01]

2.3 Homozygous Minor

4

197

Risk Ratio (M‐H, Random, 95% CI)

1.43 [0.99, 2.06]

Figures and Tables -
Comparison 12. Bupropion vs placebo ‐ rs588765 ‐ non‐Hispanic white
Comparison 13. Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

738

Risk Ratio (M‐H, Random, 95% CI)

1.40 [1.05, 1.86]

1.1 Homozygous Major

2

260

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.73, 1.80]

1.2 Heterozygous

2

370

Risk Ratio (M‐H, Random, 95% CI)

1.43 [0.99, 2.06]

1.3 Homozygous Minor

2

108

Risk Ratio (M‐H, Random, 95% CI)

2.73 [1.02, 7.36]

2 End of Treatment Show forest plot

4

975

Risk Ratio (M‐H, Random, 95% CI)

1.43 [1.19, 1.73]

2.1 Homozygous Major

4

339

Risk Ratio (M‐H, Random, 95% CI)

1.37 [1.04, 1.80]

2.2 Heterozygous

4

482

Risk Ratio (M‐H, Random, 95% CI)

1.36 [1.04, 1.79]

2.3 Homozygous Minor

4

154

Risk Ratio (M‐H, Random, 95% CI)

2.64 [1.33, 5.25]

Figures and Tables -
Comparison 13. Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic white
Comparison 14. Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

3

660

Risk Ratio (M‐H, Random, 95% CI)

1.30 [0.88, 1.92]

1.1 Homozygous Major

3

377

Risk Ratio (M‐H, Random, 95% CI)

1.17 [0.70, 1.98]

1.2 Heterozygous or Homozygous Minor

3

283

Risk Ratio (M‐H, Random, 95% CI)

1.44 [0.71, 2.91]

2 End of Treatment Show forest plot

4

693

Risk Ratio (M‐H, Random, 95% CI)

1.87 [1.36, 2.56]

2.1 Homozygous Major

4

395

Risk Ratio (M‐H, Random, 95% CI)

2.11 [1.39, 3.22]

2.2 Heterozygous or Homozygous Minor

4

298

Risk Ratio (M‐H, Random, 95% CI)

1.57 [0.93, 2.62]

Figures and Tables -
Comparison 14. Bupropion vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American
Comparison 15. Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

571

Risk Ratio (M‐H, Random, 95% CI)

1.41 [1.07, 1.87]

1.1 Homozygous Major

2

268

Risk Ratio (M‐H, Random, 95% CI)

1.21 [0.81, 1.82]

1.2 Heterozygous

2

218

Risk Ratio (M‐H, Random, 95% CI)

1.95 [1.22, 3.13]

1.3 Homozygous Minor

2

85

Risk Ratio (M‐H, Random, 95% CI)

1.13 [0.58, 2.17]

2 End of Treatment Show forest plot

4

807

Risk Ratio (M‐H, Random, 95% CI)

1.55 [1.29, 1.87]

2.1 Homozygous Major

4

367

Risk Ratio (M‐H, Random, 95% CI)

1.44 [1.11, 1.86]

2.2 Heterozygous

4

333

Risk Ratio (M‐H, Random, 95% CI)

1.69 [1.24, 2.30]

2.3 Homozygous Minor

4

107

Risk Ratio (M‐H, Random, 95% CI)

1.69 [0.96, 2.95]

Figures and Tables -
Comparison 15. Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic white
Comparison 16. Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

61

Risk Ratio (M‐H, Random, 95% CI)

1.51 [0.75, 3.04]

1.1 Homozygous Major

2

61

Risk Ratio (M‐H, Random, 95% CI)

1.51 [0.75, 3.04]

Figures and Tables -
Comparison 16. Bupropion vs placebo ‐ rs3733829 ‐ non‐Hispanic black or African American
Comparison 17. Bupropion vs placebo ‐ rs7937 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

557

Risk Ratio (M‐H, Random, 95% CI)

1.42 [1.13, 1.78]

1.1 Homozygous Major

3

159

Risk Ratio (M‐H, Random, 95% CI)

1.76 [1.13, 2.75]

1.2 Heterozygous

3

285

Risk Ratio (M‐H, Random, 95% CI)

1.30 [0.95, 1.76]

1.3 Homozygous Minor

3

113

Risk Ratio (M‐H, Random, 95% CI)

1.38 [0.82, 2.31]

Figures and Tables -
Comparison 17. Bupropion vs placebo ‐ rs7937 ‐ non‐Hispanic white
Comparison 18. Bupropion vs placebo ‐ rs7937 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

76

Risk Ratio (M‐H, Random, 95% CI)

1.56 [0.77, 3.18]

1.1 Homozygous Major

2

38

Risk Ratio (M‐H, Random, 95% CI)

1.70 [0.57, 5.10]

1.2 Heterozygous or Homozygous Minor

2

38

Risk Ratio (M‐H, Random, 95% CI)

1.57 [0.42, 5.84]

Figures and Tables -
Comparison 18. Bupropion vs placebo ‐ rs7937 ‐ non‐Hispanic black or African American
Comparison 19. Bupropion vs placebo ‐ rs1329650 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

559

Risk Ratio (M‐H, Random, 95% CI)

1.37 [1.07, 1.74]

1.1 Homozygous Major

3

280

Risk Ratio (M‐H, Random, 95% CI)

1.54 [1.07, 2.22]

1.2 Heterozygous

3

244

Risk Ratio (M‐H, Random, 95% CI)

1.31 [0.88, 1.96]

1.3 Homozygous Minor

3

35

Risk Ratio (M‐H, Random, 95% CI)

1.25 [0.33, 4.74]

Figures and Tables -
Comparison 19. Bupropion vs placebo ‐ rs1329650 ‐ non‐Hispanic white
Comparison 20. Bupropion vs placebo ‐ rs1329650 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

76

Risk Ratio (M‐H, Random, 95% CI)

1.44 [0.70, 2.99]

1.1 Homozygous Major

2

63

Risk Ratio (M‐H, Random, 95% CI)

1.62 [0.67, 3.96]

1.2 Heterozygous or Homozygous Minor

2

13

Risk Ratio (M‐H, Random, 95% CI)

0.93 [0.15, 5.70]

Figures and Tables -
Comparison 20. Bupropion vs placebo ‐ rs1329650 ‐ non‐Hispanic black or African American
Comparison 21. Bupropion vs placebo ‐ rs1028936 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

559

Risk Ratio (M‐H, Random, 95% CI)

1.39 [1.11, 1.74]

1.1 Homozygous Major

3

370

Risk Ratio (M‐H, Random, 95% CI)

1.54 [1.15, 2.06]

1.2 Heterozygous

3

175

Risk Ratio (M‐H, Random, 95% CI)

1.33 [0.75, 2.35]

1.3 Homozygous Minor

3

14

Risk Ratio (M‐H, Random, 95% CI)

1.60 [0.30, 8.49]

Figures and Tables -
Comparison 21. Bupropion vs placebo ‐ rs1028936 ‐ non‐Hispanic white
Comparison 22. Bupropion vs placebo ‐ rs1028936 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

76

Risk Ratio (M‐H, Random, 95% CI)

1.47 [0.68, 3.21]

1.1 Homozygous Major

2

65

Risk Ratio (M‐H, Random, 95% CI)

1.77 [0.74, 4.20]

1.2 Heterozygous or Homozygous Minor

2

11

Risk Ratio (M‐H, Random, 95% CI)

0.67 [0.09, 4.77]

Figures and Tables -
Comparison 22. Bupropion vs placebo ‐ rs1028936 ‐ non‐Hispanic black or African American
Comparison 23. Bupropion vs placebo ‐ rs215605 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

558

Risk Ratio (M‐H, Random, 95% CI)

1.48 [1.18, 1.87]

1.1 Homozygous Major

3

219

Risk Ratio (M‐H, Random, 95% CI)

1.77 [1.23, 2.55]

1.2 Heterozygous

3

259

Risk Ratio (M‐H, Random, 95% CI)

1.35 [0.98, 1.87]

1.3 Homozygous Minor

3

80

Risk Ratio (M‐H, Random, 95% CI)

1.12 [0.49, 2.55]

Figures and Tables -
Comparison 23. Bupropion vs placebo ‐ rs215605 ‐ non‐Hispanic white
Comparison 24. Bupropion vs placebo ‐ rs215605 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

76

Risk Ratio (M‐H, Random, 95% CI)

1.41 [0.54, 3.69]

1.1 Homozygous Major

2

49

Risk Ratio (M‐H, Random, 95% CI)

1.93 [0.15, 24.95]

1.2 Heterozygous or Homozygous Minor

2

27

Risk Ratio (M‐H, Random, 95% CI)

1.67 [0.46, 6.13]

Figures and Tables -
Comparison 24. Bupropion vs placebo ‐ rs215605 ‐ non‐Hispanic black or African American
Comparison 25. Bupropion + any NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

444

Risk Ratio (M‐H, Random, 95% CI)

1.80 [1.07, 3.03]

1.1 Homozygous Major

2

183

Risk Ratio (M‐H, Random, 95% CI)

2.11 [0.31, 14.60]

1.2 Heterozygous

2

216

Risk Ratio (M‐H, Random, 95% CI)

1.82 [1.23, 2.69]

1.3 Homozygous Minor

2

45

Risk Ratio (M‐H, Random, 95% CI)

2.84 [0.90, 8.89]

Figures and Tables -
Comparison 25. Bupropion + any NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic white
Comparison 26. Bupropion + any NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

69

Risk Ratio (M‐H, Random, 95% CI)

0.91 [0.27, 3.07]

1.1 Homozygous Major

2

58

Risk Ratio (M‐H, Random, 95% CI)

1.64 [0.56, 4.83]

1.2 Heterozygous or Homozygous Minor

2

11

Risk Ratio (M‐H, Random, 95% CI)

0.22 [0.03, 1.43]

Figures and Tables -
Comparison 26. Bupropion + any NRT vs placebo ‐ rs1051730 ‐ non‐Hispanic black or African American
Comparison 27. Bupropion + any NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

441

Risk Ratio (M‐H, Random, 95% CI)

1.79 [1.07, 2.99]

1.1 Homozygous Major

2

183

Risk Ratio (M‐H, Random, 95% CI)

2.11 [0.31, 14.60]

1.2 Heterozygous

2

215

Risk Ratio (M‐H, Random, 95% CI)

1.80 [1.22, 2.66]

1.3 Homozygous Minor

2

43

Risk Ratio (M‐H, Random, 95% CI)

2.81 [0.89, 8.88]

Figures and Tables -
Comparison 27. Bupropion + any NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic white
Comparison 28. Bupropion + any NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

69

Risk Ratio (M‐H, Random, 95% CI)

1.05 [0.46, 2.38]

1.1 Homozygous Major

2

63

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.51, 2.85]

1.2 Heterozygous or Homozygous Minor

2

6

Risk Ratio (M‐H, Random, 95% CI)

0.33 [0.03, 4.19]

Figures and Tables -
Comparison 28. Bupropion + any NRT vs placebo ‐ rs16969968 ‐ non‐Hispanic black or African American
Comparison 29. Bupropion + any NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

443

Risk Ratio (M‐H, Random, 95% CI)

1.74 [1.09, 2.77]

1.1 Homozygous Major

2

181

Risk Ratio (M‐H, Random, 95% CI)

2.20 [0.33, 14.75]

1.2 Heterozygous

2

220

Risk Ratio (M‐H, Random, 95% CI)

1.83 [1.23, 2.72]

1.3 Homozygous Minor

2

42

Risk Ratio (M‐H, Random, 95% CI)

2.12 [0.79, 5.65]

Figures and Tables -
Comparison 29. Bupropion + any NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic white
Comparison 30. Bupropion + any NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

69

Risk Ratio (M‐H, Random, 95% CI)

1.00 [0.52, 1.92]

1.1 Homozygous Major

2

38

Risk Ratio (M‐H, Random, 95% CI)

2.03 [0.39, 10.56]

1.2 Heterozygous

2

23

Risk Ratio (M‐H, Random, 95% CI)

1.03 [0.38, 2.77]

1.3 Homozygous Minor

2

8

Risk Ratio (M‐H, Random, 95% CI)

0.74 [0.26, 2.05]

Figures and Tables -
Comparison 30. Bupropion + any NRT vs placebo ‐ rs2036527 ‐ non‐Hispanic black or African American
Comparison 31. Bupropion + any NRT vs placebo ‐ rs3733829 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

442

Risk Ratio (M‐H, Random, 95% CI)

1.55 [1.20, 2.01]

1.1 Homozygous Major

2

187

Risk Ratio (M‐H, Random, 95% CI)

1.48 [0.83, 2.65]

1.2 Heterozygous

2

201

Risk Ratio (M‐H, Random, 95% CI)

1.87 [1.04, 3.36]

1.3 Homozygous Minor

2

54

Risk Ratio (M‐H, Random, 95% CI)

1.85 [0.91, 3.74]

Figures and Tables -
Comparison 31. Bupropion + any NRT vs placebo ‐ rs3733829 ‐ non‐Hispanic white
Comparison 32. Bupropion + any NRT vs placebo ‐ rs3733829 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

48

Risk Ratio (M‐H, Random, 95% CI)

0.42 [0.14, 1.24]

1.1 Homozygous Major

2

48

Risk Ratio (M‐H, Random, 95% CI)

0.42 [0.14, 1.24]

Figures and Tables -
Comparison 32. Bupropion + any NRT vs placebo ‐ rs3733829 ‐ non‐Hispanic black or African American
Comparison 33. Bupropion + any NRT vs placebo ‐ rs7937 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

442

Risk Ratio (M‐H, Random, 95% CI)

1.51 [1.16, 1.97]

1.1 Homozygous Major

2

131

Risk Ratio (M‐H, Random, 95% CI)

2.00 [0.84, 4.75]

1.2 Heterozygous

2

229

Risk Ratio (M‐H, Random, 95% CI)

1.39 [0.99, 1.94]

1.3 Homozygous Minor

2

82

Risk Ratio (M‐H, Random, 95% CI)

2.34 [0.49, 11.08]

Figures and Tables -
Comparison 33. Bupropion + any NRT vs placebo ‐ rs7937 ‐ non‐Hispanic white
Comparison 34. Bupropion + any NRT vs placebo ‐ rs7937 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

69

Risk Ratio (M‐H, Random, 95% CI)

1.06 [0.47, 2.38]

1.1 Homozygous Major

2

31

Risk Ratio (M‐H, Random, 95% CI)

1.05 [0.40, 2.73]

1.2 Heterozygous or Homozygous Minor

2

38

Risk Ratio (M‐H, Random, 95% CI)

1.08 [0.23, 4.99]

Figures and Tables -
Comparison 34. Bupropion + any NRT vs placebo ‐ rs7937 ‐ non‐Hispanic black or African American
Comparison 35. Bupropion + any NRT vs placebo ‐ rs1329650 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

442

Risk Ratio (M‐H, Random, 95% CI)

1.62 [1.10, 2.39]

1.1 Homozygous Major

2

240

Risk Ratio (M‐H, Random, 95% CI)

1.98 [1.31, 3.00]

1.2 Heterozygous

2

172

Risk Ratio (M‐H, Random, 95% CI)

1.60 [0.70, 3.67]

1.3 Homozygous Minor

2

30

Risk Ratio (M‐H, Random, 95% CI)

2.04 [0.17, 25.25]

Figures and Tables -
Comparison 35. Bupropion + any NRT vs placebo ‐ rs1329650 ‐ non‐Hispanic white
Comparison 36. Bupropion + any NRT vs placebo ‐ rs1329650 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

69

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.48, 2.41]

1.1 Homozygous Major

2

55

Risk Ratio (M‐H, Random, 95% CI)

1.00 [0.40, 2.55]

1.2 Heterozygous or Homozygous Minor

2

14

Risk Ratio (M‐H, Random, 95% CI)

1.32 [0.26, 6.80]

Figures and Tables -
Comparison 36. Bupropion + any NRT vs placebo ‐ rs1329650 ‐ non‐Hispanic black or African American
Comparison 37. Bupropion + any NRT vs placebo ‐ rs1028936 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

444

Risk Ratio (M‐H, Random, 95% CI)

1.64 [1.08, 2.49]

1.1 Homozygous Major

2

305

Risk Ratio (M‐H, Random, 95% CI)

1.89 [1.34, 2.67]

1.2 Heterozygous

2

125

Risk Ratio (M‐H, Random, 95% CI)

1.42 [0.48, 4.20]

1.3 Homozygous Minor

2

14

Risk Ratio (M‐H, Random, 95% CI)

1.93 [0.47, 8.02]

Figures and Tables -
Comparison 37. Bupropion + any NRT vs placebo ‐ rs1028936 ‐ non‐Hispanic white
Comparison 38. Bupropion + any NRT vs placebo ‐ rs1028936 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

69

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.48, 2.41]

1.1 Homozygous Major

2

57

Risk Ratio (M‐H, Random, 95% CI)

1.10 [0.43, 2.84]

1.2 Heterozygous or Homozygous Minor

2

12

Risk Ratio (M‐H, Random, 95% CI)

0.96 [0.17, 5.39]

Figures and Tables -
Comparison 38. Bupropion + any NRT vs placebo ‐ rs1028936 ‐ non‐Hispanic black or African American
Comparison 39. Bupropion + any NRT vs placebo ‐ rs215605 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

442

Risk Ratio (M‐H, Random, 95% CI)

1.72 [1.16, 2.53]

1.1 Homozygous Major

2

171

Risk Ratio (M‐H, Random, 95% CI)

2.00 [1.32, 3.03]

1.2 Heterozygous

2

200

Risk Ratio (M‐H, Random, 95% CI)

1.47 [0.60, 3.63]

1.3 Homozygous Minor

2

71

Risk Ratio (M‐H, Random, 95% CI)

2.29 [0.72, 7.27]

Figures and Tables -
Comparison 39. Bupropion + any NRT vs placebo ‐ rs215605 ‐ non‐Hispanic white
Comparison 40. Bupropion + any NRT vs placebo ‐ rs215605 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

68

Risk Ratio (M‐H, Random, 95% CI)

0.85 [0.41, 1.77]

1.1 Homozygous Major

2

36

Risk Ratio (M‐H, Random, 95% CI)

0.71 [0.29, 1.76]

1.2 Heterozygous or Homozygous Minor

2

32

Risk Ratio (M‐H, Random, 95% CI)

1.19 [0.34, 4.13]

Figures and Tables -
Comparison 40. Bupropion + any NRT vs placebo ‐ rs215605 ‐ non‐Hispanic black or African American
Comparison 41. Bupropion + any NRT vs bupropion ‐ rs1051730 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

533

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.90, 1.55]

1.1 Homozygous Major

2

206

Risk Ratio (M‐H, Random, 95% CI)

1.14 [0.54, 2.42]

1.2 Heterozygous

2

262

Risk Ratio (M‐H, Random, 95% CI)

1.22 [0.93, 1.61]

1.3 Homozygous Minor

2

65

Risk Ratio (M‐H, Random, 95% CI)

1.28 [0.68, 2.44]

Figures and Tables -
Comparison 41. Bupropion + any NRT vs bupropion ‐ rs1051730 ‐ non‐Hispanic white
Comparison 42. Bupropion + any NRT vs bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

87

Risk Ratio (M‐H, Random, 95% CI)

0.70 [0.37, 1.31]

1.1 Homozygous Major

2

66

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.40, 1.49]

1.2 Heterozygous or Homozygous Minor

2

21

Risk Ratio (M‐H, Random, 95% CI)

0.33 [0.05, 2.19]

Figures and Tables -
Comparison 42. Bupropion + any NRT vs bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American
Comparison 43. Bupropion + any NRT vs bupropion ‐ rs16969968 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

531

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.90, 1.55]

1.1 Homozygous Major

2

206

Risk Ratio (M‐H, Random, 95% CI)

1.14 [0.54, 2.42]

1.2 Heterozygous

2

262

Risk Ratio (M‐H, Random, 95% CI)

1.22 [0.93, 1.61]

1.3 Homozygous Minor

2

63

Risk Ratio (M‐H, Random, 95% CI)

1.27 [0.66, 2.44]

Figures and Tables -
Comparison 43. Bupropion + any NRT vs bupropion ‐ rs16969968 ‐ non‐Hispanic white
Comparison 44. Bupropion + any NRT vs bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

87

Risk Ratio (M‐H, Random, 95% CI)

0.69 [0.37, 1.27]

1.1 Homozygous Major

2

74

Risk Ratio (M‐H, Random, 95% CI)

0.73 [0.38, 1.40]

1.2 Heterozygous or Homozygous Minor

2

13

Risk Ratio (M‐H, Random, 95% CI)

0.41 [0.06, 2.76]

Figures and Tables -
Comparison 44. Bupropion + any NRT vs bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American
Comparison 45. Bupropion + any NRT vs bupropion ‐ rs2036527 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

532

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.91, 1.52]

1.1 Homozygous Major

2

204

Risk Ratio (M‐H, Random, 95% CI)

1.17 [0.54, 2.52]

1.2 Heterozygous

2

264

Risk Ratio (M‐H, Random, 95% CI)

1.21 [0.92, 1.60]

1.3 Homozygous Minor

2

64

Risk Ratio (M‐H, Random, 95% CI)

1.24 [0.68, 2.25]

Figures and Tables -
Comparison 45. Bupropion + any NRT vs bupropion ‐ rs2036527 ‐ non‐Hispanic white
Comparison 46. Bupropion + any NRT vs bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

87

Risk Ratio (M‐H, Random, 95% CI)

0.66 [0.35, 1.23]

1.1 Homozygous Major

2

50

Risk Ratio (M‐H, Random, 95% CI)

0.56 [0.23, 1.35]

1.2 Heterozygous or Homozygous Minor

2

37

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.32, 1.90]

Figures and Tables -
Comparison 46. Bupropion + any NRT vs bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American
Comparison 47. Bupropion + any NRT vs bupropion ‐ rs3733829 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

531

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.96, 1.39]

1.1 Homozygous Major

2

236

Risk Ratio (M‐H, Random, 95% CI)

1.19 [0.77, 1.84]

1.2 Heterozygous

2

229

Risk Ratio (M‐H, Random, 95% CI)

1.11 [0.82, 1.51]

1.3 Homozygous Minor

2

66

Risk Ratio (M‐H, Random, 95% CI)

1.34 [0.80, 2.25]

Figures and Tables -
Comparison 47. Bupropion + any NRT vs bupropion ‐ rs3733829 ‐ non‐Hispanic white
Comparison 48. Bupropion + any NRT vs bupropion ‐ rs3733829 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

94

Risk Ratio (M‐H, Random, 95% CI)

0.49 [0.25, 0.99]

1.1 Homozygous Major

2

65

Risk Ratio (M‐H, Random, 95% CI)

0.43 [0.18, 1.01]

1.2 Heterozygous or Homozygous Minor

2

29

Risk Ratio (M‐H, Random, 95% CI)

0.73 [0.13, 4.20]

Figures and Tables -
Comparison 48. Bupropion + any NRT vs bupropion ‐ rs3733829 ‐ non‐Hispanic black or African American
Comparison 49. Bupropion + any NRT vs bupropion ‐ rs7937 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

533

Risk Ratio (M‐H, Random, 95% CI)

1.16 [0.95, 1.42]

1.1 Homozygous Major

2

145

Risk Ratio (M‐H, Random, 95% CI)

1.01 [0.65, 1.59]

1.2 Heterozygous

2

272

Risk Ratio (M‐H, Random, 95% CI)

1.27 [0.81, 2.00]

1.3 Homozygous Minor

2

116

Risk Ratio (M‐H, Random, 95% CI)

1.29 [0.90, 1.84]

Figures and Tables -
Comparison 49. Bupropion + any NRT vs bupropion ‐ rs7937 ‐ non‐Hispanic white
Comparison 50. Bupropion + any NRT vs bupropion ‐ rs7937 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

87

Risk Ratio (M‐H, Random, 95% CI)

0.75 [0.39, 1.43]

1.1 Homozygous Major

2

33

Risk Ratio (M‐H, Random, 95% CI)

0.61 [0.13, 2.86]

1.2 Heterozygous or Homozygous Minor

2

54

Risk Ratio (M‐H, Random, 95% CI)

0.73 [0.27, 1.93]

Figures and Tables -
Comparison 50. Bupropion + any NRT vs bupropion ‐ rs7937 ‐ non‐Hispanic black or African American
Comparison 51. Bupropion + any NRT vs bupropion ‐ rs1329650 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

531

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.97, 1.49]

1.1 Homozygous Major

2

279

Risk Ratio (M‐H, Random, 95% CI)

1.22 [0.66, 2.25]

1.2 Heterozygous

2

214

Risk Ratio (M‐H, Random, 95% CI)

1.22 [0.92, 1.62]

1.3 Homozygous Minor

2

38

Risk Ratio (M‐H, Random, 95% CI)

1.68 [0.89, 3.17]

Figures and Tables -
Comparison 51. Bupropion + any NRT vs bupropion ‐ rs1329650 ‐ non‐Hispanic white
Comparison 52. Bupropion + any NRT vs bupropion ‐ rs1329650 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

87

Risk Ratio (M‐H, Random, 95% CI)

0.63 [0.33, 1.20]

1.1 Homozygous Major

2

76

Risk Ratio (M‐H, Random, 95% CI)

0.59 [0.30, 1.15]

1.2 Heterozygous or Homozygous Minor

2

11

Risk Ratio (M‐H, Random, 95% CI)

1.2 [0.17, 8.24]

Figures and Tables -
Comparison 52. Bupropion + any NRT vs bupropion ‐ rs1329650 ‐ non‐Hispanic black or African American
Comparison 53. Bupropion + any NRT vs bupropion ‐ rs1028936 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

533

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.92, 1.50]

1.1 Homozygous Major

2

359

Risk Ratio (M‐H, Random, 95% CI)

1.09 [0.86, 1.37]

1.2 Heterozygous

2

159

Risk Ratio (M‐H, Random, 95% CI)

1.30 [0.62, 2.75]

1.3 Homozygous Minor

2

15

Risk Ratio (M‐H, Random, 95% CI)

2.17 [0.51, 9.18]

Figures and Tables -
Comparison 53. Bupropion + any NRT vs bupropion ‐ rs1028936 ‐ non‐Hispanic white
Comparison 54. Bupropion + any NRT vs bupropion ‐ rs1028936 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

87

Risk Ratio (M‐H, Random, 95% CI)

0.63 [0.33, 1.20]

1.1 Homozygous Major

2

76

Risk Ratio (M‐H, Random, 95% CI)

0.59 [0.30, 1.15]

1.2 Heterozygous or Homozygous Minor

2

11

Risk Ratio (M‐H, Random, 95% CI)

1.2 [0.17, 8.24]

Figures and Tables -
Comparison 54. Bupropion + any NRT vs bupropion ‐ rs1028936 ‐ non‐Hispanic black or African American
Comparison 55. Bupropion + any NRT vs bupropion ‐ rs215605 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

532

Risk Ratio (M‐H, Random, 95% CI)

1.17 [0.93, 1.47]

1.1 Homozygous Major

2

211

Risk Ratio (M‐H, Random, 95% CI)

1.28 [0.91, 1.80]

1.2 Heterozygous

2

241

Risk Ratio (M‐H, Random, 95% CI)

1.00 [0.69, 1.45]

1.3 Homozygous Minor

2

80

Risk Ratio (M‐H, Random, 95% CI)

1.61 [0.64, 4.08]

Figures and Tables -
Comparison 55. Bupropion + any NRT vs bupropion ‐ rs215605 ‐ non‐Hispanic white
Comparison 56. Bupropion + any NRT vs bupropion ‐ rs215605 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

87

Risk Ratio (M‐H, Random, 95% CI)

0.71 [0.37, 1.35]

1.1 Homozygous Major

2

49

Risk Ratio (M‐H, Random, 95% CI)

0.51 [0.09, 2.94]

1.2 Heterozygous or Homozygous Minor

2

38

Risk Ratio (M‐H, Random, 95% CI)

0.71 [0.26, 1.93]

Figures and Tables -
Comparison 56. Bupropion + any NRT vs bupropion ‐ rs215605 ‐ non‐Hispanic black or African American
Comparison 57. Active NRT ‐ rs1051730 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

7

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

7

1559

Risk Ratio (M‐H, Random, 95% CI)

0.92 [0.71, 1.19]

1.2 Heterozygous vs Homozygous Minor

7

1650

Risk Ratio (M‐H, Random, 95% CI)

0.91 [0.75, 1.11]

2 End of Treatment Show forest plot

5

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

5

1200

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.73, 1.06]

2.2 Heterozygous vs Homozygous Minor

5

1291

Risk Ratio (M‐H, Random, 95% CI)

0.93 [0.79, 1.10]

Figures and Tables -
Comparison 57. Active NRT ‐ rs1051730 ‐ non‐Hispanic white
Comparison 58. Active NRT ‐ rs1051730 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

187

Risk Ratio (M‐H, Random, 95% CI)

1.08 [0.26, 4.57]

1.2 Heterozygous vs Homozygous Minor

2

56

Risk Ratio (M‐H, Random, 95% CI)

1.11 [0.25, 4.99]

Figures and Tables -
Comparison 58. Active NRT ‐ rs1051730 ‐ non‐Hispanic black or African American
Comparison 59. Active NRT ‐ rs16969968 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

392

Risk Ratio (M‐H, Random, 95% CI)

2.24 [0.92, 5.45]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

392

Risk Ratio (M‐H, Random, 95% CI)

2.75 [1.08, 7.02]

Figures and Tables -
Comparison 59. Active NRT ‐ rs16969968 ‐ non‐Hispanic black or African American
Comparison 60. Active NRT ‐ rs588765 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

433

Risk Ratio (M‐H, Random, 95% CI)

1.05 [0.80, 1.37]

1.2 Heterozygous vs Homozygous Minor

3

546

Risk Ratio (M‐H, Random, 95% CI)

0.99 [0.76, 1.29]

2 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

3

429

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.76, 1.18]

2.2 Heterozygous vs Homozygous Minor

3

542

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.77, 1.17]

Figures and Tables -
Comparison 60. Active NRT ‐ rs588765 ‐ non‐Hispanic white
Comparison 61. Active NRT ‐ rs2036527 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

501

Risk Ratio (M‐H, Random, 95% CI)

0.79 [0.60, 1.03]

1.2 Heterozygous vs Homozygous Minor

2

579

Risk Ratio (M‐H, Random, 95% CI)

0.83 [0.63, 1.10]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

2

501

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.59, 1.35]

2.2 Heterozygous vs Homozygous Minor

2

579

Risk Ratio (M‐H, Random, 95% CI)

1.00 [0.61, 1.64]

Figures and Tables -
Comparison 61. Active NRT ‐ rs2036527 ‐ non‐Hispanic white
Comparison 62. Active NRT ‐ rs2036527 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

391

Risk Ratio (M‐H, Random, 95% CI)

1.25 [0.87, 1.81]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

391

Risk Ratio (M‐H, Random, 95% CI)

1.73 [1.20, 2.49]

Figures and Tables -
Comparison 62. Active NRT ‐ rs2036527 ‐ non‐Hispanic black or African American
Comparison 63. Active NRT ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

866

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.51, 1.76]

1.2 Heterozygous vs Homozygous Minor

3

321

Risk Ratio (M‐H, Random, 95% CI)

0.81 [0.42, 1.60]

2 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

3

866

Risk Ratio (M‐H, Random, 95% CI)

0.93 [0.71, 1.23]

2.2 Heterozygous vs Homozygous Minor

3

321

Risk Ratio (M‐H, Random, 95% CI)

0.85 [0.58, 1.26]

Figures and Tables -
Comparison 63. Active NRT ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white
Comparison 64. Active NRT ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

461

Risk Ratio (M‐H, Random, 95% CI)

0.92 [0.50, 1.67]

1.2 Heterozygous vs Homozygous Minor

2

649

Risk Ratio (M‐H, Random, 95% CI)

1.12 [0.66, 1.90]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

2

461

Risk Ratio (M‐H, Random, 95% CI)

0.97 [0.77, 1.23]

2.2 Heterozygous vs Homozygous Minor

2

649

Risk Ratio (M‐H, Random, 95% CI)

0.94 [0.74, 1.18]

Figures and Tables -
Comparison 64. Active NRT ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white
Comparison 65. Active NRT‐NMR ‐ non‐Hispanic white or black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Normal NMR vs Slow NMR

2

718

Risk Ratio (M‐H, Random, 95% CI)

0.54 [0.37, 0.78]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Normal NMR vs Slow NMR

2

718

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.58, 1.03]

Figures and Tables -
Comparison 65. Active NRT‐NMR ‐ non‐Hispanic white or black or African American
Comparison 66. Bupropion ‐ rs1051730 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

4

316

Risk Ratio (M‐H, Random, 95% CI)

1.27 [0.67, 2.43]

1.2 Heterozygous vs Homozygous Minor

4

390

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.65, 2.03]

2 End of Treatment Show forest plot

6

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

6

386

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.88, 1.50]

2.2 Heterozygous vs Homozygous Minor

6

480

Risk Ratio (M‐H, Random, 95% CI)

1.04 [0.81, 1.33]

Figures and Tables -
Comparison 66. Bupropion ‐ rs1051730 ‐ non‐Hispanic white
Comparison 67. Bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

63

Risk Ratio (M‐H, Random, 95% CI)

0.83 [0.36, 1.95]

2 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

3

84

Risk Ratio (M‐H, Random, 95% CI)

0.94 [0.51, 1.72]

Figures and Tables -
Comparison 67. Bupropion ‐ rs1051730 ‐ non‐Hispanic black or African American
Comparison 68. Bupropion ‐ rs16969968 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

160

Risk Ratio (M‐H, Random, 95% CI)

1.47 [0.96, 2.25]

1.2 Heterozygous vs Homozygous Minor

3

216

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.79, 1.84]

Figures and Tables -
Comparison 68. Bupropion ‐ rs16969968 ‐ non‐Hispanic white
Comparison 69. Bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

294

Risk Ratio (M‐H, Random, 95% CI)

0.62 [0.31, 1.21]

2 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

3

315

Risk Ratio (M‐H, Random, 95% CI)

0.79 [0.48, 1.32]

Figures and Tables -
Comparison 69. Bupropion ‐ rs16969968 ‐ non‐Hispanic black or African American
Comparison 70. Bupropion ‐ rs588765 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

4

304

Risk Ratio (M‐H, Random, 95% CI)

0.83 [0.52, 1.34]

1.2 Heterozygous vs Homozygous Minor

4

401

Risk Ratio (M‐H, Random, 95% CI)

0.90 [0.66, 1.21]

2 End of Treatment Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

4

304

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.69, 1.14]

2.2 Heterozygous vs Homozygous Minor

4

400

Risk Ratio (M‐H, Random, 95% CI)

0.96 [0.76, 1.22]

Figures and Tables -
Comparison 70. Bupropion ‐ rs588765 ‐ non‐Hispanic white
Comparison 71. Bupropion ‐ rs2036527 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

208

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.33, 1.81]

1.2 Heterozygous vs Homozygous Minor

2

269

Risk Ratio (M‐H, Random, 95% CI)

0.83 [0.51, 1.37]

2 End of Treatment Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

4

277

Risk Ratio (M‐H, Random, 95% CI)

1.16 [0.79, 1.70]

2.2 Heterozygous vs Homozygous Minor

4

361

Risk Ratio (M‐H, Random, 95% CI)

0.96 [0.61, 1.51]

Figures and Tables -
Comparison 71. Bupropion ‐ rs2036527 ‐ non‐Hispanic white
Comparison 72. Bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

3

331

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.55, 1.46]

2 End of Treatment Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

4

352

Risk Ratio (M‐H, Random, 95% CI)

1.24 [0.87, 1.76]

Figures and Tables -
Comparison 72. Bupropion ‐ rs2036527 ‐ non‐Hispanic black or African American
Comparison 73. Bupropion ‐ rs3733829 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

191

Risk Ratio (M‐H, Random, 95% CI)

0.90 [0.56, 1.46]

1.2 Heterozygous vs Homozygous Minor

2

161

Risk Ratio (M‐H, Random, 95% CI)

1.06 [0.65, 1.71]

2 End of Treatment Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

4

259

Risk Ratio (M‐H, Random, 95% CI)

1.02 [0.73, 1.40]

2.2 Heterozygous vs Homozygous Minor

4

237

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.70, 1.36]

Figures and Tables -
Comparison 73. Bupropion ‐ rs3733829 ‐ non‐Hispanic white
Comparison 74. Bupropion ‐ rs3733829 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

46

Risk Ratio (M‐H, Random, 95% CI)

1.05 [0.37, 2.99]

Figures and Tables -
Comparison 74. Bupropion ‐ rs3733829 ‐ non‐Hispanic black or African American
Comparison 75. Bupropion ‐ rs7937 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

159

Risk Ratio (M‐H, Random, 95% CI)

1.00 [0.71, 1.40]

1.2 Heterozygous vs Homozygous Minor

3

238

Risk Ratio (M‐H, Random, 95% CI)

0.90 [0.65, 1.23]

Figures and Tables -
Comparison 75. Bupropion ‐ rs7937 ‐ non‐Hispanic white
Comparison 76. Bupropion ‐ rs7937 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

23

Risk Ratio (M‐H, Random, 95% CI)

1.16 [0.32, 4.26]

1.2 Heterozygous vs Homozygous Minor

2

27

Risk Ratio (M‐H, Random, 95% CI)

0.72 [0.18, 2.93]

Figures and Tables -
Comparison 76. Bupropion ‐ rs7937 ‐ non‐Hispanic black or African American
Comparison 77. Bupropion ‐ rs1329650 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

186

Risk Ratio (M‐H, Random, 95% CI)

0.85 [0.54, 1.35]

1.2 Heterozygous vs Homozygous Minor

3

163

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.56, 1.42]

Figures and Tables -
Comparison 77. Bupropion ‐ rs1329650 ‐ non‐Hispanic white
Comparison 78. Bupropion ‐ rs1329650 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

47

Risk Ratio (M‐H, Random, 95% CI)

1.46 [0.35, 6.01]

Figures and Tables -
Comparison 78. Bupropion ‐ rs1329650 ‐ non‐Hispanic black or African American
Comparison 79. Bupropion ‐ rs1028936 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

221

Risk Ratio (M‐H, Random, 95% CI)

0.81 [0.42, 1.55]

1.2 Heterozygous vs Homozygous Minor

3

112

Risk Ratio (M‐H, Random, 95% CI)

0.81 [0.40, 1.64]

Figures and Tables -
Comparison 79. Bupropion ‐ rs1028936 ‐ non‐Hispanic white
Comparison 80. Bupropion ‐ rs1028936 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

47

Risk Ratio (M‐H, Random, 95% CI)

1.46 [0.35, 6.01]

Figures and Tables -
Comparison 80. Bupropion ‐ rs1028936 ‐ non‐Hispanic black or African American
Comparison 81. Bupropion ‐ rs215605 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

170

Risk Ratio (M‐H, Random, 95% CI)

1.61 [0.87, 3.00]

1.2 Heterozygous vs Homozygous Minor

3

199

Risk Ratio (M‐H, Random, 95% CI)

1.56 [0.79, 3.06]

Figures and Tables -
Comparison 81. Bupropion ‐ rs215605 ‐ non‐Hispanic white
Comparison 82. Bupropion ‐ rs215605 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

47

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.54, 2.44]

Figures and Tables -
Comparison 82. Bupropion ‐ rs215605 ‐ non‐Hispanic black or African American
Comparison 83. Varenicline ‐ rs16969968 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

358

Risk Ratio (M‐H, Random, 95% CI)

0.94 [0.71, 1.25]

1.2 Heterozygous vs Homozygous Minor

2

438

Risk Ratio (M‐H, Random, 95% CI)

0.99 [0.75, 1.30]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

2

358

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.78, 1.24]

2.2 Heterozygous vs Homozygous Minor

2

438

Risk Ratio (M‐H, Random, 95% CI)

0.97 [0.77, 1.22]

Figures and Tables -
Comparison 83. Varenicline ‐ rs16969968 ‐ non‐Hispanic white
Comparison 84. Varenicline ‐ rs588765 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

354

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.91, 1.60]

1.2 Heterozygous vs Homozygous Minor

2

465

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.90, 1.54]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

2

354

Risk Ratio (M‐H, Random, 95% CI)

1.14 [0.91, 1.43]

2.2 Heterozygous vs Homozygous Minor

2

465

Risk Ratio (M‐H, Random, 95% CI)

1.10 [0.89, 1.37]

Figures and Tables -
Comparison 84. Varenicline ‐ rs588765 ‐ non‐Hispanic white
Comparison 85. Bupropion + any NRT ‐ rs1051730 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

138

Risk Ratio (M‐H, Random, 95% CI)

1.10 [0.67, 1.78]

1.2 Heterozygous vs Homozygous Minor

2

155

Risk Ratio (M‐H, Random, 95% CI)

1.11 [0.69, 1.80]

Figures and Tables -
Comparison 85. Bupropion + any NRT ‐ rs1051730 ‐ non‐Hispanic white
Comparison 86. Bupropion + any NRT ‐ rs1051730 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

40

Risk Ratio (M‐H, Random, 95% CI)

2.26 [0.36, 14.38]

Figures and Tables -
Comparison 86. Bupropion + any NRT ‐ rs1051730 ‐ non‐Hispanic black or African American
Comparison 87. Bupropion + any NRT ‐ rs16969968 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

136

Risk Ratio (M‐H, Random, 95% CI)

1.12 [0.67, 1.85]

1.2 Heterozygous vs Homozygous Minor

2

153

Risk Ratio (M‐H, Random, 95% CI)

1.13 [0.68, 1.86]

Figures and Tables -
Comparison 87. Bupropion + any NRT ‐ rs16969968 ‐ non‐Hispanic white
Comparison 88. Bupropion + any NRT ‐ rs16969968 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

40

Risk Ratio (M‐H, Random, 95% CI)

1.66 [0.27, 10.32]

Figures and Tables -
Comparison 88. Bupropion + any NRT ‐ rs16969968 ‐ non‐Hispanic black or African American
Comparison 89. Bupropion + any NRT ‐ rs2036527 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

135

Risk Ratio (M‐H, Random, 95% CI)

1.12 [0.70, 1.79]

1.2 Heterozygous vs Homozygous Minor

2

156

Risk Ratio (M‐H, Random, 95% CI)

1.04 [0.65, 1.66]

Figures and Tables -
Comparison 89. Bupropion + any NRT ‐ rs2036527 ‐ non‐Hispanic white
Comparison 90. Bupropion + any NRT ‐ rs2036527 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

28

Risk Ratio (M‐H, Random, 95% CI)

0.51 [0.06, 4.51]

1.2 Heterozygous vs Homozygous Minor

2

17

Risk Ratio (M‐H, Random, 95% CI)

0.70 [0.03, 15.98]

Figures and Tables -
Comparison 90. Bupropion + any NRT ‐ rs2036527 ‐ non‐Hispanic black or African American
Comparison 91. Bupropion + any NRT ‐ rs3733829 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

144

Risk Ratio (M‐H, Random, 95% CI)

0.94 [0.66, 1.34]

1.2 Heterozygous vs Homozygous Minor

2

153

Risk Ratio (M‐H, Random, 95% CI)

0.79 [0.55, 1.14]

Figures and Tables -
Comparison 91. Bupropion + any NRT ‐ rs3733829 ‐ non‐Hispanic white
Comparison 92. Bupropion + any NRT ‐ rs3733829 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

40

Risk Ratio (M‐H, Random, 95% CI)

0.36 [0.13, 0.99]

Figures and Tables -
Comparison 92. Bupropion + any NRT ‐ rs3733829 ‐ non‐Hispanic black or African American
Comparison 93. Bupropion + any NRT ‐ rs7937 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

128

Risk Ratio (M‐H, Random, 95% CI)

0.79 [0.57, 1.10]

1.2 Heterozygous vs Homozygous Minor

2

194

Risk Ratio (M‐H, Random, 95% CI)

0.81 [0.51, 1.28]

Figures and Tables -
Comparison 93. Bupropion + any NRT ‐ rs7937 ‐ non‐Hispanic white
Comparison 94. Bupropion + any NRT ‐ rs7937 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

40

Risk Ratio (M‐H, Random, 95% CI)

1.29 [0.12, 13.56]

Figures and Tables -
Comparison 94. Bupropion + any NRT ‐ rs7937 ‐ non‐Hispanic black or African American
Comparison 95. Bupropion + any NRT ‐ rs1329650 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

170

Risk Ratio (M‐H, Random, 95% CI)

0.64 [0.43, 0.94]

1.2 Heterozygous vs Homozygous Minor

2

117

Risk Ratio (M‐H, Random, 95% CI)

0.71 [0.50, 1.03]

Figures and Tables -
Comparison 95. Bupropion + any NRT ‐ rs1329650 ‐ non‐Hispanic white
Comparison 96. Bupropion + any NRT ‐ rs1329650 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

40

Risk Ratio (M‐H, Random, 95% CI)

0.54 [0.15, 1.94]

Figures and Tables -
Comparison 96. Bupropion + any NRT ‐ rs1329650 ‐ non‐Hispanic black or African American
Comparison 97. Bupropion + any NRT ‐ rs1028936 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

193

Risk Ratio (M‐H, Random, 95% CI)

0.63 [0.37, 1.07]

1.2 Heterozygous vs Homozygous Minor

2

85

Risk Ratio (M‐H, Random, 95% CI)

0.75 [0.42, 1.32]

Figures and Tables -
Comparison 97. Bupropion + any NRT ‐ rs1028936 ‐ non‐Hispanic white
Comparison 98. Bupropion + any NRT ‐ rs1028936 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

40

Risk Ratio (M‐H, Random, 95% CI)

0.54 [0.15, 1.94]

Figures and Tables -
Comparison 98. Bupropion + any NRT ‐ rs1028936 ‐ non‐Hispanic black or African American
Comparison 99. Bupropion + any NRT ‐ rs215605 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

148

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.84, 1.66]

1.2 Heterozygous vs Homozygous Minor

2

162

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.61, 1.26]

Figures and Tables -
Comparison 99. Bupropion + any NRT ‐ rs215605 ‐ non‐Hispanic white
Comparison 100. Bupropion + any NRT ‐ rs215605 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

40

Risk Ratio (M‐H, Random, 95% CI)

0.76 [0.04, 13.56]

Figures and Tables -
Comparison 100. Bupropion + any NRT ‐ rs215605 ‐ non‐Hispanic black or African American
Comparison 101. Placebo ‐ rs1051730 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

6

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

6

533

Risk Ratio (M‐H, Random, 95% CI)

1.29 [0.86, 1.92]

1.2 Heterozygous vs Homozygous Minor

6

597

Risk Ratio (M‐H, Random, 95% CI)

1.08 [0.72, 1.62]

2 End of Treatment Show forest plot

7

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

7

542

Risk Ratio (M‐H, Random, 95% CI)

1.39 [0.91, 2.13]

2.2 Heterozygous vs Homozygous Minor

7

605

Risk Ratio (M‐H, Random, 95% CI)

1.24 [0.81, 1.89]

Figures and Tables -
Comparison 101. Placebo ‐ rs1051730 ‐ non‐Hispanic white
Comparison 102. Placebo ‐ rs1051730 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

63

Risk Ratio (M‐H, Random, 95% CI)

0.73 [0.08, 6.73]

2 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

3

83

Risk Ratio (M‐H, Random, 95% CI)

0.76 [0.24, 2.45]

Figures and Tables -
Comparison 102. Placebo ‐ rs1051730 ‐ non‐Hispanic black or African American
Comparison 103. Placebo ‐ rs16969968 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

162

Risk Ratio (M‐H, Random, 95% CI)

1.05 [0.51, 2.14]

1.2 Heterozygous vs Homozygous Minor

2

211

Risk Ratio (M‐H, Random, 95% CI)

0.79 [0.32, 1.96]

2 End of Treatment Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

4

218

Risk Ratio (M‐H, Random, 95% CI)

1.55 [0.68, 3.53]

2.2 Heterozygous vs Homozygous Minor

4

276

Risk Ratio (M‐H, Random, 95% CI)

1.34 [0.51, 3.53]

Figures and Tables -
Comparison 103. Placebo ‐ rs16969968 ‐ non‐Hispanic white
Comparison 104. Placebo ‐ rs16969968 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

3

584

Risk Ratio (M‐H, Random, 95% CI)

0.74 [0.42, 1.33]

2 End of Treatment Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

4

596

Risk Ratio (M‐H, Random, 95% CI)

0.55 [0.35, 0.86]

Figures and Tables -
Comparison 104. Placebo ‐ rs16969968 ‐ non‐Hispanic black or African American
Comparison 105. Placebo ‐ rs588765 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

5

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

5

383

Risk Ratio (M‐H, Random, 95% CI)

1.04 [0.69, 1.57]

1.2 Heterozygous vs Homozygous Minor

5

470

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.72, 1.58]

2 End of Treatment Show forest plot

5

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

5

362

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.63, 1.21]

2.2 Heterozygous vs Homozygous Minor

5

404

Risk Ratio (M‐H, Random, 95% CI)

1.08 [0.80, 1.46]

Figures and Tables -
Comparison 105. Placebo ‐ rs588765 ‐ non‐Hispanic white
Comparison 106. Placebo ‐ rs588765 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

566

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.80, 1.79]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

566

Risk Ratio (M‐H, Random, 95% CI)

1.12 [0.71, 1.77]

Figures and Tables -
Comparison 106. Placebo ‐ rs588765 ‐ non‐Hispanic black or African American
Comparison 107. Placebo ‐ rs2036527 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

160

Risk Ratio (M‐H, Random, 95% CI)

1.85 [0.77, 4.44]

1.2 Heterozygous vs Homozygous Minor

2

209

Risk Ratio (M‐H, Random, 95% CI)

1.58 [0.66, 3.77]

2 End of Treatment Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

4

216

Risk Ratio (M‐H, Random, 95% CI)

1.98 [0.91, 4.35]

2.2 Heterozygous vs Homozygous Minor

4

275

Risk Ratio (M‐H, Random, 95% CI)

1.86 [0.94, 3.69]

Figures and Tables -
Comparison 107. Placebo ‐ rs2036527 ‐ non‐Hispanic white
Comparison 108. Placebo ‐ rs2036527 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

4

629

Risk Ratio (M‐H, Random, 95% CI)

1.12 [0.71, 1.77]

2 End of Treatment Show forest plot

5

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Heterozygous or Homozygous Minor

5

641

Risk Ratio (M‐H, Random, 95% CI)

1.08 [0.71, 1.64]

Figures and Tables -
Comparison 108. Placebo ‐ rs2036527 ‐ non‐Hispanic black or African American
Comparison 109. Placebo ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

387

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.37, 3.16]

1.2 Heterozygous vs Homozygous Minor

3

212

Risk Ratio (M‐H, Random, 95% CI)

0.60 [0.22, 1.63]

2 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

3

387

Risk Ratio (M‐H, Random, 95% CI)

1.08 [0.51, 2.29]

2.2 Heterozygous vs Homozygous Minor

3

212

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.61, 1.29]

Figures and Tables -
Comparison 109. Placebo ‐ DRD‐4 (exon 3 48 bp) ‐ non‐Hispanic white
Comparison 110. Placebo ‐ rs3733829 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

2

162

Risk Ratio (M‐H, Random, 95% CI)

0.84 [0.46, 1.51]

1.2 Heterozygous vs Homozygous Minor

2

142

Risk Ratio (M‐H, Random, 95% CI)

0.66 [0.35, 1.26]

2 End of Treatment Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major vs Homozygous Minor

4

215

Risk Ratio (M‐H, Random, 95% CI)

1.23 [0.74, 2.05]

2.2 Heterozygous vs Homozygous Minor

4

203

Risk Ratio (M‐H, Random, 95% CI)

0.97 [0.57, 1.65]

Figures and Tables -
Comparison 110. Placebo ‐ rs3733829 ‐ non‐Hispanic white
Comparison 111. Placebo ‐ rs7937 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

113

Risk Ratio (M‐H, Random, 95% CI)

0.81 [0.45, 1.45]

1.2 Heterozygous vs Homozygous Minor

3

160

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.57, 1.60]

Figures and Tables -
Comparison 111. Placebo ‐ rs7937 ‐ non‐Hispanic white
Comparison 112. Placebo ‐ rs7937 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

29

Risk Ratio (M‐H, Random, 95% CI)

1.17 [0.27, 5.04]

Figures and Tables -
Comparison 112. Placebo ‐ rs7937 ‐ non‐Hispanic black or African American
Comparison 113. Placebo ‐ rs1329650 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

129

Risk Ratio (M‐H, Random, 95% CI)

0.81 [0.18, 3.62]

1.2 Heterozygous vs Homozygous Minor

3

116

Risk Ratio (M‐H, Random, 95% CI)

0.80 [0.39, 1.63]

Figures and Tables -
Comparison 113. Placebo ‐ rs1329650 ‐ non‐Hispanic white
Comparison 114. Placebo ‐ rs1329650 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

29

Risk Ratio (M‐H, Random, 95% CI)

0.72 [0.19, 2.78]

Figures and Tables -
Comparison 114. Placebo ‐ rs1329650 ‐ non‐Hispanic black or African American
Comparison 115. Placebo ‐ rs1028936 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

163

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.29, 3.14]

1.2 Heterozygous vs Homozygous Minor

3

77

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.36, 4.03]

Figures and Tables -
Comparison 115. Placebo ‐ rs1028936 ‐ non‐Hispanic white
Comparison 116. Placebo ‐ rs1028936 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

29

Risk Ratio (M‐H, Random, 95% CI)

0.49 [0.18, 1.32]

Figures and Tables -
Comparison 116. Placebo ‐ rs1028936 ‐ non‐Hispanic black or African American
Comparison 117. Placebo ‐ rs215605 ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Homozygous Minor

3

129

Risk Ratio (M‐H, Random, 95% CI)

0.97 [0.52, 1.82]

1.2 Heterozygous vs Homozygous Minor

3

140

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.63, 2.12]

Figures and Tables -
Comparison 117. Placebo ‐ rs215605 ‐ non‐Hispanic white
Comparison 118. Placebo ‐ rs215605 ‐ non‐Hispanic black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major vs Heterozygous or Homozygous Minor

2

29

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.03, 38.58]

Figures and Tables -
Comparison 118. Placebo ‐ rs215605 ‐ non‐Hispanic black or African American
Comparison 119. Placebo ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Homozygous Major or Heterozygous vs Homozygous Minor

2

151

Risk Ratio (M‐H, Random, 95% CI)

0.75 [0.32, 1.79]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Homozygous Major or Heterozygous vs Homozygous Minor

2

151

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.83, 1.38]

Figures and Tables -
Comparison 119. Placebo ‐ SLC6A4 (Promoter) ‐ non‐Hispanic white
Comparison 120. Placebo ‐ NMR ‐ non‐Hispanic white or black or African American

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six‐Month Abstinence Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Normal NMR vs Slow NMR

2

699

Risk Ratio (M‐H, Random, 95% CI)

1.02 [0.70, 1.48]

2 End of Treatment Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Normal NMR vs Slow NMR

2

718

Risk Ratio (M‐H, Random, 95% CI)

0.63 [0.35, 1.14]

Figures and Tables -
Comparison 120. Placebo ‐ NMR ‐ non‐Hispanic white or black or African American